96-4663. Consolidation, Elimination, and Clarification of Various Regulations

[Federal Register Volume 61, Number 44 (Tuesday, March 5, 1996)]
[Proposed Rules]
[Pages 8503-8534]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-4663]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Parts 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308,
1309, 1310, 1311, 1312, 1313, and 1316

[DEA Number 139P]
RIN Number 1117-AA33

Consolidation, Elimination, and Clarification of Various
Regulations

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: DEA proposes to amend the language in title 21, Code of
Federal Regulations, parts 1300 through 1316. In concert with the
President's National Performance Review, Regulatory Reinvention
Initiative (NPR), DEA proposes to consolidate, eliminate, and clarify
many of its regulations to address areas of confusion frequently raised
by the pharmaceutical, chemical, and health care industries; and to
correct inaccurate citations, office designations, and typographical
errors.

DATES: Written comments or objections must be received by July 3, 1996.

ADDRESSES: Comments and objections should be submitted in quintuplicate
to the Deputy Administrator, Drug Enforcement Administration,
Washington, DC 20537, Attention: DEA Federal Register Representative/
CCR.

FOR FURTHER INFORMATION CONTACT: G. Thomas Gitchel, Chief, Liaison and
Policy Section, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Telephone (202) 307-7297.

SUPPLEMENTARY INFORMATION: A comprehensive review has been conducted of
title 21, Code of Federal Regulations (21 CFR), parts 1300 through
1316. Title 21 contains the rules and regulations by which DEA
implements the Controlled Substances Act, the Narcotic Addict Treatment
Act, the Controlled Substances Import/Export Act, the Chemical
Diversion and Trafficking Act, and the Domestic Chemical Diversion
Control Act. These regulations are designed to detect and deter the
diversion of controlled substances and listed chemicals. DEA undertook
this review to update, simplify, and consolidate its regulations in
concert with the President's Regulatory Reform Initiative under the
NPR; to clarify areas of confusion which have been raised by the
pharmaceutical, chemical, and health care industries; and to correct
inaccurate citations, office designations and typographical errors. In
this effort, DEA intends to reduce some of the regulatory burden on the
affected industries. The changes proposed herein build upon DEA's
longstanding commitment to internal self-examination, to respond to
technological advances, and to work with industry to develop the most
effective and least intrusive methods of preventing and detecting the
diversion of controlled substances and listed chemicals.
Among the changes being proposed, which are further described
below, are the consolidation into a chart of the frequency of
registration, coincident activities, and fee schedules; allowing
manufacturers more latitude to set individual labeling standards;
reducing the frequency of ARCOS reports from monthly to quarterly, and
reducing the number of transactions to be reported by manufacturers;
permitting some pharmacies to file prescriptions without marking them
with a red ``C'', to transfer prescriptions for refill purposes more
than once, and to retain faxed prescriptions as original documents for
patients in home hospice care; and combining and streamlining various
reporting, recordkeeping, and inventory requirements.
The following summarizes the changes proposed to be made to each
part of the regulations:
Part 1300
DEA is proposing to move the definitions set out in 21 CFR parts
1301 through 1313 into a new part 1300. This will provide a single
source for definition of the terms used in 21 CFR parts 1301 through
1313, avoiding the need for duplicate definitions in the various parts.
The definitions set out in Part 1316 will remain listed in that part
due to the specificity of the definitions to the subject matter of the
part.
Part 1301
DEA is proposing to amend 21 CFR, part 1301 to provide a simple and
clear set of requirements concerning the registration of manufacturers,
distributors, dispensers, importers and exporters of controlled
substances. In this regard, DEA is proposing to incorporate into 21
CFR, part 1301 the requirements relating to the registration of
importers and exporters which were previously set out in 21 CFR, part
1311.
In order to provide easier reference to the primary regulations
regarding registration (including separate registration for independent
activities, coincident activities, the application forms and fees
required for registration and reregistration, and the registration
period for the various activities) DEA is proposing to amend 21 CFR,
part 1301 to list such requirements in table form. Use of the table
form allows for ``at-a-glance'' reference to the fundamental
regulations concerning the registration requirements, rather than
requiring reference to multiple pages of text in separate sections.
In addition to revising the format of 21 CFR, part 1301, DEA is
proposing to transfer the definitions previously listed in Sec. 1301.02
to the proposed new part 1300, and to remove Secs. 1301.27, 1301.29,
and 1301.53, relating to civil defense authorities, provisional
registration of narcotic treatment programs (NTP), and waiver and
modification of rules in hearings, respectively. Sections 1301.27 and
1301.29 are obsolete and Sec. 1301.53 is duplicated by Sec. 1316.44.
With respect to civil defense authorities, DEA will continue to work
with the appropriate Federal and state agencies to insure that the
proper policies and procedures are in place to deal with the
availability and

[[Page 8504]]
security of controlled substances during emergencies. Further, the fee
exemption provisions (formerly in Sec. 1301.13 and now in Sec. 1301.21)
and the provision regarding when a registrant may apply for
reregistration (formerly in Sec. 1301.31(b) and now in Sec. 1301.13(b))
have been amended. The fee exemption provision has been amended to
provide that Federal, state or local officials who must obtain an
individual practitioner registration in order to carry out their
official duties are exempted from the fees for registration and
reregistration. This action is being taken to insure that those
individual government practitioners who are not able to practice under
the registration number of a hospital or clinic are subject to the same
exemption as those government physicians carrying out official duties
in such facilities. The reregistration provision has been amended to
allow that a person registered as either a bulk manufacturer of
Schedule I or II controlled substances or an importer of Schedule I or
II controlled substances may apply to be reregistered no more than 120
days prior to the expiration date of his/her registration. The current
limitation of no more than 60 days prior to the expiration date does
not allow sufficient time prior to the applicant's expiration date to
satisfy the notice and comment and hearing procedures required under
Secs. 1301.33 and 1301.34 of this chapter. The additional 60 days
should provide sufficient time to allow for satisfaction of those
requirements for most applications prior to the expiration date.
However, in no circumstances will DEA grant such an applicant
reregistration more than 60 days prior to the applicant's registration
expiration date.
DEA is also proposing to incorporate the language found in
Sec. 1307.12 of this chapter into the coincident activities table and
the language found in Sec. 1307.14 into Sec. 1301.62. Additionally, DEA
is proposing to combine Secs. 1301.62 and 1301.63 into one section and
revise the new section to allow that a registration cannot be assigned
or transferred unless specific, written authority has been granted by
the Administration.
The proposed changes will result in a substantial restructuring of
part 1301, including the redesignation of most of the sections within
the part. Only the sections relating to the Security Requirements
(Sec. 1301.71-1301.76) and Employee Screening--Non-Practitioners
(Sec. 1301.90-1301.93) are unchanged. For the sake of clarity, DEA is
proposing in the regulatory text to remove the old Secs. 1301.11
through 1301.63 and replace them with new Secs. 1301.11 through
1301.52. While the appearance of the new sections is significantly
changed, readers should keep in mind that there are only minor changes
to the specific regulatory requirements contained in the old parts 1301
and 1311.
Part 1302
This part contains the requirements governing the labeling and
packaging of controlled substances pursuant to sections 305 and 1008(e)
of the Act (21 U.S.C. 825 and 958(e)). The proposed changes made in
part 1302 would move the definitions into Part 1300 for ease of
reference and, in general, allow more latitude to the registrant in the
design of labels for products which contain controlled substances.
While continuing to require an identifiable marking on labels of a
commercial container which contains a controlled substance, the
proposed changes would allow the registrant to meet the requirement by
its own design of a label and placement of the required symbol.
Further, language regarding labeling requirements at the inception of
the Controlled Substances Act (on May 1, 1971) has been proposed to be
removed as no longer necessary. The effective date for implementing the
labeling requirements for substances transferred or added to a schedule
is proposed to be established in the final order. Finally, the
requirement for sealing of a commercial package is proposed to be
amended to include all controlled substances, making it consistent with
the Federal Food, Drug, and Cosmetic Act, and to allow more latitude in
the design of the seal, while retaining the primary purpose of a seal
which is to detect tampering of the commercial package.
Part 1303
This part contains the procedures governing the establishment of
production and manufacturing quotas for basic classes of controlled
substances listed in Schedules I and II. Changes are being proposed in
this part to correct inaccurate citations and typographical errors and
to move the definitions to part 1300 for ease of reference.
Part 1304
This part sets forth inventory and recordkeeping requirements for
registrants who handle controlled substances. In accordance with 21
U.S.C. 827 and 958(e), registrants who manufacture, distribute, or
dispense controlled substances must maintain complete and accurate
records of such substances manufactured, received, sold, delivered or
otherwise disposed of. Modifications to several sections of part 1304
are being proposed to eliminate the requirement for reports which are
outdated, to remove redundancies in recordkeeping and inventory
requirements, to change obsolete references, and to correct
typographical errors.
Section 1304.02 is proposed to be revised to remove all definitions
to Part 1300.
Section 1304.03 is proposed to be revised to combine researcher
activities into one paragraph, thereby eliminating redundancies in the
recordkeeping requirements.
Section 1304.04 is proposed to be revised to correct a
typographical error in paragraph (a), to update language in paragraph
(e), and amend paragraph (h)(2) to permit pharmacies with automatic
data processing systems to file Schedule III-V prescriptions without
marking them with a red ``C''.
Section 1304.11 is proposed to be revised to combine all general
requirements for inventories thereby eliminating redundancies.
Paragraphs (b) and (c) were combined and the frequency statement was
revised to permit the biennial inventory to be taken on any date as
long as it is within two years of the previous biennial inventory; the
requirements contained in Secs. 1304.12, 1304.13, 1304.14, 1304.15,
1304.16, 1304.17, 1304.18 and 1304.19 were combined and included in
1304.11. In Sec. 1304.12, the reference to the May 1, 1971 date is
proposed to be deleted. Paragraph references are proposed to be changed
to reflect revisions.
Section 1304.21 paragraph (a): The May 1, 1971 date is proposed to
be deleted and paragraph references changed to reflect revisions.
Sections 1304.22, 1304.23, 1304.24, 1304.25 and 1304.26 are
proposed to be combined. Paragraph references are proposed to be
changed to reflect revisions.
Sections 1304.31 through 1304.38 are proposed to be revised,
combined, or removed to delete obsolete forms and references, and
reflect changes to manufacturer reporting from existing regulations to
conform with current practice. Reporting requirements are proposed to
be revised to reflect changes in frequency of reporting (from monthly
to quarterly) and to reduce the number of transactions (i.e., quality
control samples, manufacturing waste, etc.) required to be reported by
manufacturers.
Part 1305
This part contains the procedures governing the issuance, use, and
preservation of order forms pursuant to

[[Page 8505]]
section 308 of the Act (21 U.S.C. 828). The changes proposed to be made
in part 1305, in general, delete redundant requirements and move the
definitions into part 1300 for ease of reference. Section 1305.05,
Power of Attorney, is amended only to correct certain citations;
however, the existing Power of Attorney format is repeated in its
entirety. Additionally, the Official Order Form for Schedule I & II
Controlled Substances contains instructions that need not be repeated
in the regulations. Regulations requiring reporting of lost or stolen
Order Forms are modified to standardize reporting to local DEA offices
of responsibility.
Part 1306
This part contains the specific regulatory requirements for the
issuance, filling, and filing of prescriptions. Changes to this part
are being proposed to reduce regulatory requirements for pharmacies.
Additional changes are being made to correct typographical errors in
the existing text.
Section 1306.02 contains a number of definitions which are proposed
to be moved to part 1300 for ease of reference.
Section 1306.11 establishes the requirements for prescriptions for
controlled substances listed in Schedule II. Under Sec. 1306.11, the
length of time a pharmacy is permitted to obtain a written prescription
to cover an emergency oral prescription for a Schedule II controlled
substance is 72 hours. Many pharmacists have expressed the view that
there often is not enough time to meet their obligation within the time
permitted. DEA is therefore proposing to extend the time allowed to
obtain the written prescription from 72 hours to 7 days.
This same section permits pharmacists to dispense Schedule II
narcotics to patients in Long Term Care Facilities (LTCFs) pursuant to
prescriptions transmitted by facsimile. The facsimile then acts as the
original written prescription for recordkeeping purposes. DEA is
proposing to add a paragraph to Sec. 1306.11 to give pharmacies the
same authority to fill Schedule II narcotic prescriptions transmitted
by facsimile for patients in a home hospice setting as exists for
patients in LTCFs. The physician issuing the prescription will be
required to note that the patient is a hospice patient on the face of
the faxed prescription.
Section 1306.13 contains the rules for the partial filling of
Schedule II prescriptions. A prescription for a Schedule II controlled
substance written for a patient in a LTCF or for a patient with a
medical diagnosis documenting a terminal illness may be filled in
partial quantities to include individual dosage units. Section
1306.13(b) requires that prior to any subsequent partial filling the
pharmacist must determine that the additional partial fillings are
necessary. DEA is proposing to remove this requirement.
The requirements for Schedule III and IV controlled substances are
currently delineated separately from those in Schedule V. In order to
more clearly differentiate those requirements that are identical from
those that are not, where appropriate, identical rules affecting the
controlled substances in Schedule V are proposed to be merged with
those for Schedule III and IV. DEA is proposing to add Schedule V
references to Sec. 1306.21 and delete the corresponding Sec. 1306.31.
The language in these two sections is virtually identical and,
therefore, will have no effect on the requirements currently in place.
Several typographical errors and an obsolete term are proposed to
be corrected in Sec. 1306.22.
Section 1306.23, which currently allows for the partial filling of
Schedule III and IV prescriptions, is proposed to be expanded to add
Schedule V controlled substances.
Section 1306.25, which refers to the rules for filing Schedule III
and IV prescriptions contained in Sec. 1304.04(h), is proposed to be
removed and replaced by a new paragraph (Sec. 1306.24(c)).
Section 1306.26 establishes the rules for the transfer between
pharmacies of prescription information for Schedules III, IV, and V
controlled substances for refill purposes. A principal requirement for
transferring prescription information is that the original prescription
may be transferred on a one time basis only. This limitation was and is
extremely important in preventing illegal and unauthorized refills from
being dispensed. The prevention of diversion through unauthorized
refills is significantly impacted by the ability of pharmacists and
investigators to locate and confirm the authenticity of original
prescription records. However, in situations where the prescription
information, to include the entire refill history, is immediately
accessible to the pharmacist, some exceptions to the one time only rule
are proposed.
DEA is proposing to permit pharmacies sharing a real-time, on-line
electronic database, to transfer prescription information for refill
purposes for Schedule III, IV, and V controlled substances as often as
refills are authorized by law and the original prescription. In
addition to the requirements currently imposed on prescription
transfers, it is proposed that a pharmacy filling a transferred
prescription will be required to record the dates of all previous
refills.
Part 1307
This part is a miscellaneous part which addresses the application
of state law and other Federal Law, exceptions to regulations, special
exceptions for manufacture and distribution of controlled substances,
disposal of controlled substances, and special exempt persons. Changes
to this part are being proposed to correct citation errors and
omissions and to consolidate similar requirements. Section 1307.01
contains a definition which is proposed to be moved to part 1300. DEA
proposes to remove Sec. 1307.12 and include its provisions in the chart
of coincident activities contained in Part 1301. DEA proposes to
incorporate Sec. 1307.14, Distribution upon discontinuance or transfer
of business, with the redesignated Sec. 1301.52, Transfer of
registration. Section 1307.21 is proposed to be amended so that the
requirements for reporting controlled substances to be disposed of will
be uniform for all registrants regardless of whether or not they file
reports to ARCOS.
Part 1308
This part sets forth the schedules of controlled substances and
mechanisms for scheduling, rescheduling, or decontrolling a substance.
Section 1308.04 is proposed to be removed as unnecessary since it is
outdated. The following tables are proposed to be removed which contain
information given out routinely to the industry and is available upon
request: Section 1308.24--Exempt Chemical Preparations; Sec. 1308.26--
Excluded Veterinary Anabolic Steroid Implant Products; Sec. 1308.32--
Exempted prescription products; and Sec. 1308.34--Exempt Anabolic
Steroid Products. The sections will contain a reference on the
procedure to request a copy of the tables.
Sections 1308.43, 1308.46, and 1308.47 relating to hearings are
proposed to be removed as their requirements are already contained in
part 1316. Proposed to be added to Section 1308.42 is a sentence which
provides information on where to locate additional information on
hearings related to this part.
Part 1309
Part 1309 is proposed to be amended by moving the definitions set
out in Sec. 1309.02 into part 1300. This will

[[Page 8506]]
provide a centralized source for all definitions for parts 1301 through
1313.
Further, Secs. 1309.53 and 1309.57 are proposed to be removed, as
they duplicate Sec. 1316.44 and 1316.67 respectively. Sections 1309.54
through 1309.56 are proposed to be redesignated as Secs. 1309.53
through 1309.55. In addition, Secs. 1309.21 (a) and (b), 1309.25 (a)
and (b), and 1309.71(a)(2) are proposed to be amended to change the
citation from Sec. 1310.01(f)(1)(iv) to Sec. 1300.01(c)(28)(i)(D).
Part 1310
Part 1310 is proposed to be amended by moving the definitions set
out in Sec. 1310.01 into part 1300. Sections 1310.05 and 1310.08 will
be amended to remove references to definitions in Sec. 1310.01. Section
1310.10(a) is proposed to be amended to change the citation from
Sec. 1310.01(f)(1)(iv) to Sec. 1300.01(c)(28)(i)(D) and
Secs. 1310.14(a) and 1310.15(d) are proposed to be amended to change
the citation from Sec. 1310.01(f)(1)(iv)(A) to
Sec. 1300.01(c)(28)(i)(D)(1). Finally, Sec. 1310.09 is proposed to be
removed, as this section was applicable only during the initial
chemical registration period.
Part 1311
This part is proposed to be removed and reserved. The requirements
contained in part 1311 have been incorporated into the proposed
revisions to part 1301.
Part 1312
This part contains the procedures governing the importation,
exportation, transshipment, and intransit shipment of controlled
substances. Changes are being proposed in this part to correct
inaccurate citations and typographical errors, to update office
designations and addresses, and to move the definitions to part 1300
for ease of reference.
Part 1313
Part 1313 is proposed to be amended by moving the definitions set
out in Sec. 1313.02 into part 1300. In addition, Secs. 1313.15, 1313.21
and 1313.24 are proposed to be amended to remove references to the
definitions in Sec. 1313.02.
Part 1316
This part contains the regulatory requirements and authorities
related to Administrative Inspections, Protection of Researchers and
Research Subjects, Enforcement Proceedings, Administrative Hearings,
Seizure, Forfeiture, and Disposition of Property and Expedited
Forfeiture Proceedings for Certain Property. Changes to this part are
being proposed to correct citation errors and omissions and to
consolidate similar requirements. DEA proposes to revise Sec. 1316.13
to replace the present schedule of inspections with a system where the
frequency of inspections will be determined by the history of the
registrant, potential for diversion, or the amount of controlled
substances found in the illicit market. DEA will focus inspection
resources on diversion prevention and problem areas, reducing the
intended frequency of inspections of registrants with a demonstrated
record of compliance. This revision only applies to distributors of
controlled substances listed in Schedules II through V and
manufacturers of controlled substances listed in Schedules III through
V. The yearly inspection for manufacturers of controlled substances
listed in Schedules I and II and distributors of controlled substances
listed in Schedule I remains unchanged. This proposal is intended to
reduce the expenditure of time and effort, both on the part of DEA and
the registrants who have shown a history of compliance in the past and
continue to comply with the requirements of the CSA.
The Deputy Administrator, in accordance with the Regulatory
Flexibility Act (5 U.S.C. 605(b)), has reviewed this proposed
regulation and by approving it certifies that this proposed regulation
will not have a significant economic impact on a substantial number of
small entities. This proposed regulation will streamline the current
regulations set out in title 21, Code of Federal Regulations, parts
1300 to end and to provide regulatory relief to registrants.
This proposed regulation has been drafted in accordance with
Executive Order 12866, section 1(b), Principles of Regulation. The
Office of Managment and Budget has reviewed this proposed rule and
determined that it is not a ``significant regulatory action'' under
Executive Order 12866, section 3(f), Regulatory Planning and Review.
This regulation will not have substantial direct effects on the
States, on the relationship between the national government and the
States, or on distribution of power and responsibilities among the
various levels of government. Therefore, in accordance with Executive
Order 12612, it is determined that this rule does not have sufficient
federalism implications to warrant the preparation of a Federalism
Assessment.

List of Subjects in 21 CFR Parts 1300-1316

Administrative practice and procedure, Drug traffic control,
Security measures, Exports, Imports, Labeling, Packaging and
containers, Reporting requirements, Prescription drugs, Narcotics, List
I and List II chemicals, Research, Seizures and forfeitures.
21 CFR Part 1300 is proposed to be added to read as follows:

PART 1300--DEFINITIONS

Sec.
1300.01 Definitions relating to controlled substances.
1300.02 Definitions relating to listed chemicals.

Authority: 21 U.S.C. 802, 871(b), 951, 958(f).

Sec. 1300.01 Definitions relating to controlled substances.

[[Page 8507]]

(xv) Methenolone;
(xvi) Methyltestosterone;
(xvii) Mibolerone;
(xviii) Nandrolone;
(xix) Norethandrolone;
(xx) Oxandrolone;
(xxi) Oxymesterone;
(xxii) Oxymetholone;
(xxiii) Stanolone;
(xxiv) Stanozolol;
(xxv) Testolactone;
(xxvi) Testosterone;
(xxvii) Trenbolone; and
(xxviii) Any salt, ester, or isomer of a drug or substance
described or listed in this paragraph, if that salt, ester, or isomer
promotes muscle growth. Except such term does not include an anabolic
steroid which is expressly intended for administration through implants
to cattle or other nonhuman species and which has been approved by the
Secretary of Health and Human Services for such administration. If any
person prescribes, dispenses, or distributes such steroid for human
use, such person shall be considered to have prescribed, dispensed, or
distributed an anabolic steroid within the meaning of this paragraph.
(5) The term basic class means, as to controlled substances listed
in Schedules I and II:
(i) Each of the opiates, including its isomers, esters, ethers,
salts, and salts of isomers, esters, and ethers whenever the existence
of such isomers, esters, ethers, and salts is possible within the
specific chemical designation, listed in Sec. 1308.11(b) of this
chapter;
(ii) Each of the opium derivatives, including its salts, isomers,
and salts of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation,
listed in Sec. 1308.11(c) of this chapter;
(iii) Each of the hallucinogenic substances, including its salts,
isomers, and salts of isomers whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical
designation, listed in Sec. 1308.11(d) of this chapter;
(iv) Each of the following substances, whether produced directly or
indirectly by extraction from substances of vegetable origin, or
independently by means of chemical synthesis, or by a combination of
extraction and chemical synthesis:
(A) Opium, including raw opium, opium extracts, opium fluid
extracts, powdered opium, granulated opium, deodorized opium and
tincture of opium;
(B) Apomorphine;
(C) Codeine;
(D) Etorphine hydrochloride;
(E) Ethylmorphine;
(F) Hydrocodone;
(G) Hydromorphone;
(H) Metopon;
(I) Morphine;
(J) Oxycodone;
(K) Oxymorphone;
(L) Thebaine;
(M) Mixed alkaloids of opium listed in Section 1308.12(b)(2) of
this chapter;
(N) Cocaine; and
(O) Ecgonine;
(v) Each of the opiates, including its isomers, esters, ethers,
salts, and salts of isomers, esters, and ethers whenever the existence
of such isomers, esters, ethers, and salts is possible within the
specific chemical designation, listed in Sec. 1308.12(c) of this
chapter; and
(vi) Methamphetamine, its salts, isomers, and salts of its isomers;
(vii) Amphetamine, its salts, optical isomers, and salts of its
optical isomers;
(viii) Phenmetrazine and its salts;
(ix) Methylphenidate;
(x) Each of the substances having a depressant effect on the
central nervous system, including its salts, isomers, and salts of
isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation, listed in
Sec. 1308.12(e) of this chapter.
(6) The term commercial container means any bottle, jar, tube,
ampule, or other receptacle in which a substance is held for
distribution or dispensing to an ultimate user, and in addition, any
box or package in which the receptacle is held for distribution or
dispensing to an ultimate user. The term commercial container does not
include any package liner, package insert or other material kept with
or within a commercial container, nor any carton, crate, drum, or other
package in which commercial containers are stored or are used for
shipment of controlled substances.
(7) The term compounder means any person engaging in maintenance or
detoxification treatment who also mixes, prepares, packages or changes
the dosage form of a narcotic drug listed in Schedules II, III, IV or V
for use in maintenance or detoxification treatment by another narcotic
treatment program.
(8) The term Controlled Substance has the meaning given in section
802(6) of Title 21, United States Code (U.S.C.).
(9) The term customs territory of the United States means the
several States, the District of Columbia, and Puerto Rico.
(10) The term detoxification treatment means the dispensing, for a
period of time as specified below, of a narcotic drug or narcotic drugs
in decreasing doses to an individual to alleviate adverse physiological
or psychological effects incident to withdrawal from the continuous or
sustained use of a narcotic drug and as a method of bringing the
individual to a narcotic drug-free state within such period of time.
There are two types of detoxification treatment: Short-term
detoxification treatment and long-term detoxification treatment.
(i) Short-term detoxification treatment is for a period not in
excess of 30 days.
(ii) Long-term detoxification treatment is for a period more than
30 days but not in excess of 180 days.
(11) The term dispenser means an individual practitioner,
institutional practitioner, pharmacy or pharmacist who dispenses a
controlled substance.
(12) The term export means, with respect to any article, any taking
out or removal of such article from the jurisdiction of the United
States (whether or not such taking out or removal constitutes an
exportation within the meaning of the customs and related laws of the
United States).
(13) The term exporter includes every person who exports, or who
acts as an export broker for exportation of, controlled substances
listed in any schedule.
(14) The term hearing means:
(i) In part 1301 of this chapter, any hearing held for the
granting, denial, revocation, or suspension of a registration pursuant
to sections 303, 304, and 1008 of the Act (21 U.S.C. 823, 824 and 958).
(ii) In part 1303 of this chapter, any hearing held regarding the
determination of aggregate production quota or the issuance,
adjustment, suspension, or denial of a procurement quota or an
individual manufacturing quota.
(iii) In part 1308 of this chapter, any hearing held for the
issuance, amendment, or repeal of any rule issuable pursuant to section
201 of the Act (21 U.S.C. 811).
(15) The term home infusion pharmacy means a pharmacy which
compounds solutions for direct administration to a patient in a private
residence, Long Term Care Facility or hospice setting by means of
parenteral, intravenous, intramuscular, subcutaneous or intraspinal
infusion.
(16) The term import means, with respect to any article, any
bringing in or introduction of such article into either the
jurisdiction of the United States or the customs territory of the
United States, and from the jurisdiction of the United States into the
customs territory of the United States (whether or not such bringing in
or introduction constitutes an importation within the

[[Page 8508]]
meaning of the tariff laws of the United States).
(17) The term importer includes every person who imports, or who
acts as an import broker for importation of, controlled substances
listed in any schedule.
(18) The term individual practitioner means a physician, dentist,
veterinarian, or other individual licensed, registered, or otherwise
permitted, by the United States or the jurisdiction in which he/she
practices, to dispense a controlled substance in the course of
professional practice, but does not include a pharmacist, a pharmacy,
or an institutional practitioner.
(19) The term institutional practitioner means a hospital or other
person (other than an individual) licensed, registered, or otherwise
permitted, by the United States or the jurisdiction in which it
practices, to dispense a controlled substance in the course of
professional practice, but does not include a pharmacy.
(20) The term interested person means any person adversely affected
or aggrieved by any rule or proposed rule issuable pursuant to section
201 of the Act (21 U.S.C. 811).
(21) The term inventory means all factory and branch stocks in
finished form of a basic class of controlled substance manufactured or
otherwise acquired by a registrant, whether in bulk, commercial
containers, or contained in pharmaceutical preparations in the
possession of the registrant (including stocks held by the registrant
under separate registration as a manufacturer, importer, exporter, or
distributor).
(22) The term isomer means the optical isomer, except as used in
Sec. 1308.11(d) and Sec. 1308.12(b)(4). As used in Sec. 1308.11(d), the
term isomer means the optical, positional, or geometric isomer. As used
in Sec. 1308.12(b)(4), the term isomer means the optical or geometric
isomer.
(23) The term jurisdiction of the United States means the customs
territory of the United States, the Virgin Islands, the Canal Zone,
Guam, American Samoa, and the Trust Territories of the Pacific Islands.
(24) The term label means any display of written, printed, or
graphic matter placed upon the commercial container of any controlled
substance by any manufacturer of such substance.
(25) The term labeling means all labels and other written, printed,
or graphic matter:
(i) Upon any controlled substance or any of its commercial
containers or wrappers, or
(ii) accompanying such controlled substance.
(26) The term Long Term Care Facility (LTCF) means a nursing home,
retirement care, mental care or other facility or institution which
provides extended health care to resident patients.
(27) The term maintenance treatment means the dispensing for a
period in excess of twenty-one days, of a narcotic drug or narcotic
drugs in the treatment of an individual for dependence upon heroin or
other morphine-like drug.
(28) The term manufacture means the producing, preparation,
propagation, compounding, or processing of a drug or other substance or
the packaging or repackaging of such substance, or the labeling or
relabeling of the commercial container of such substance, but does not
include the activities of a practitioner who, as an incident to his/her
administration or dispensing such substance in the course of his/her
professional practice, prepares, compounds, packages or labels such
substance. The term manufacturer means a person who manufactures a drug
or other substance, whether under a registration as a manufacturer or
under authority of registration as a researcher or chemical analyst.
(29) The term mid-level practitioner means an individual
practitioner, other than a physician, dentist, veterinarian, or
podiatrist, who is licensed, registered, or otherwise permitted by the
United States or the jurisdiction in which he/she practices, to
dispense a controlled substance in the course of professional practice.
Examples of mid-level practitioners include, but are not limited to,
health care providers such as nurse practitioners, nurse midwives,
nurse anesthetists, clinical nurse specialists and physician assistants
who are authorized to dispense controlled substances by the state in
which they practice.
(30) The term name means the official name, common or usual name,
chemical name, or brand name of a substance.
(31) The term narcotic drug means any of the following whether
produced directly or indirectly by extraction from substances of
vegetable origin or independently by means of chemical synthesis or by
a combination of extraction and chemical synthesis:
(i) Opium, opiates, derivatives of opium and opiates, including
their isomers, esters, ethers, salts, and salts of isomers, esters, and
ethers whenever the existence of such isomers, esters, ethers and salts
is possible within the specific chemical designation. Such term does
not include the isoquinoline alkaloids of opium.
(ii) Poppy straw and concentrate of poppy straw.
(iii) Coca leaves, except coca leaves and extracts of coca leaves
from which cocaine, ecgonine and derivatives of ecgonine or their salts
have been removed.
(iv) Cocaine, its salts, optical and geometric isomers, and salts
of isomers.
(v) Ecgonine, its derivatives, their salts, isomers and salts of
isomers.
(vi) Any compound, mixture, or preparation which contains any
quantity of any of the substances referred to in paragraphs (b)(31) (i)
through (v) of this section.
(32) The term narcotic treatment program means a program engaged in
maintenance and/or detoxification treatment with narcotic drugs.
(33) The term net disposal means, for a stated period, the quantity
of a basic class of controlled substance distributed by the registrant
to another person, plus the quantity of that basic class used by the
registrant in the production of (or converted by the registrant into)
another basic class of controlled substance or a noncontrolled
substance, plus the quantity of that basic class otherwise disposed of
by the registrant, less the quantity of that basic class returned to
the registrant by any purchaser, and less the quantity of that basic
class distributed by the registrant to another registered manufacturer
of that basic class for purposes other than use in the production of,
or conversion into, another basic class of controlled substance or a
noncontrolled substance or in the manufacture of dosage forms of that
basic class.
(34) The term pharmacist means any pharmacist licensed by a State
to dispense controlled substances, and shall include any other person
(e.g., pharmacist intern) authorized by a State to dispense controlled
substances under the supervision of a pharmacist licensed by such
State.
(35) The term person includes any individual, corporation,
government or governmental subdivision or agency, business trust,
partnership, association, or other legal entity.
(36) The term prescription means an order for medication which is
dispensed to or for an ultimate user but does not include an order for
medication which is dispensed for immediate administration to the
ultimate user. (e.g., an order to dispense a drug to a bed patient for
immediate administration in a hospital is not a prescription.)
(37) The term proceeding means all actions taken for the issuance,
amendment, or repeal of any rule issued pursuant to section 201 of the
Act (21

[[Page 8509]]
U.S.C. 811), commencing with the publication by the Administrator of
the proposed rule, amended rule, or repeal in the Federal Register.
(38) The term purchaser means any registered person entitled to
obtain and execute order forms pursuant to Sec. 1305.04 and 1305.06.
(39) The term readily retrievable means that certain records are
kept by automatic data processing systems or other electronic or
mechanized recordkeeping systems in such a manner that they can be
separated out from all other records in a reasonable time and/or
records are kept on which certain items are asterisked, redlined, or in
some other manner visually identifiable apart from other items
appearing on the records.
(40) The terms register and registration refer only to registration
required and permitted by sections 303 or 1007 of the Act (21 U.S.C.
823 or 957).
(41) The term registrant means any person who is registered
pursuant to either section 303 or section 1008 of the Act (21 U.S.C.
823 or 958).
(42) The term supplier means any registered person entitled to fill
order forms pursuant to Sec. 1305.08.

Sec. 1300.02 Definitions relating to listed chemicals.

(a) Any term not defined in this part shall have the definition set
forth in section 102 of the Act (21 U.S.C. 802), except that certain
terms used in part 1316 of this chapter are defined at the beginning of
each subpart of that part.
(b) As used in parts 1309, 1310 and 1313 of this chapter, the
following terms shall have the meaning specified:
(1) The term Act means the Controlled Substances Act, as amended
(84 Stat. 1242; 21 U.S.C. 801) and/or the Controlled Substances Import
and Export Act, as amended (84 Stat. 1285; 21 U.S.C. 951) as amended.
(2) The term Administration means the Drug Enforcement
Administration.
(3) The term Administrator means the Administrator of the Drug
Enforcement Administration. The Administrator has been delegated
authority under the Act by the Attorney General (28 CFR 0.100).
(4) The terms broker and trader mean any individual, corporation,
corporate division, partnership, association, or other legal entity
which assists in arranging an international transaction in a listed
chemical by--
(i) Negotiating contracts;
(ii) Serving as an agent or intermediary; or
(iii) Fulfilling a formal obligation to complete the transaction by
bringing together a buyer and seller, a buyer and transporter, or a
seller and transporter, or by receiving any form of compensation for so
doing.
(5) The term chemical export means transferring ownership or
control, or the sending or taking of threshold quantities of listed
chemicals out of the United States (whether or not such sending or
taking out constitutes an exportation within the meaning of the Customs
and related laws of the United States).
(6) The term chemical exporter is a regulated person who, as the
principal party in interest in the export transaction, has the power
and responsibility for determining and controlling the sending of the
listed chemical out of the United States.
(7) The term chemical import means with respect to a listed
chemical, any bringing in or introduction of such listed chemical into
either the jurisdiction of the United States or into the Customs
territory of the United States (whether or not such bringing in or
introduction constitutes an importation within the meaning of the
tariff laws of the United States).
(8) The term chemical importer is a regulated person who, as the
principal party in interest in the import transaction, has the power
and responsibility for determining and controlling the bringing in or
introduction of the listed chemical into the United States.
(9) The term chemical mixture means a combination of two or more
chemical substances, at least one of which is not a listed chemical,
except that such term does not include any combination of a listed
chemical with another chemical that is present solely as an impurity or
which has been created to evade the requirements of the Act.
(10) The term customs territory of the United States means the
several States, the District of Columbia, and Puerto Rico.
(11) The term encapsulating machine means any manual, semi-
automatic, or fully automatic equipment which may be used to fill
shells or capsules with any powdered, granular, semi-solid, or liquid
material.
(12) The term established business relationship with a foreign
customer means the regulated person has exported a listed chemical at
least once within the past six months, or twice within the past twelve
months to a foreign manufacturer, distributor, or end user of the
chemical that has an established business in the foreign country with a
fixed street address. A person or business which functions as a broker
or intermediary is not a customer within the meaning of this section.
The term also means that the regulated person has provided the
Administration with the following information in accordance with the
Waiver of 15-day advance notice requirements of Sec. 1313.24 of this
chapter:
(i) The name and street address of the chemical exporter and of
each regular customer;
(ii) The telephone number, telex number, contact person, and where
available, the facsimile number for the chemical exporter and for each
regular customer;
(iii) The nature of the regular customer's business (i.e.,
importer, exporter, distributor, manufacturer, etc.), and if known, the
use to which the listed chemical or chemicals will be applied;
(iv) The duration of the business relationship;
(v) The frequency and number of transactions occurring during the
preceding 12-month period;
(vi) the amounts and the listed chemical or chemicals involved in
regulated transactions between the chemical exporter and regular
customer;
(vii) The method of delivery (direct shipment or through a broker
or forwarding agent); and
(viii) Other information that the chemical exporter considers
relevant for determining whether a customer is a regular customer.
(13) The term established record as an importer means that the
regulated person has imported a listed chemical at least once within
the past six months, or twice within the past twelve months from a
foreign supplier. The term also means that the regulated person has
provided the Administration with the following information in
accordance with the waiver of the 15-day advance notice requirements of
Sec. 1313.15 of this chapter:
(i) The name, DEA registration number (where applicable), street
address, telephone number, telex number, and, where available, the
facsimile number of the regulated person and of each foreign supplier;
and
(ii) The frequency and number of transactions occurring during the
preceding 12 month period.
(14) The term hearing means any hearing held for the granting,
denial, revocation, or suspension of a registration pursuant to
sections 303, 304, and 1008 of the Act (21 U.S.C. 823, 824 and 958).
(15) The term international transaction means a transaction
involving the shipment of a listed chemical across an international
border (other than a United States border) in which a broker or trader
located in the United States participates.

[[Page 8510]]

(16) The term jurisdiction of the United States means the customs
territory of the United States, the Virgin Islands, the Canal Zone,
Guam, American Samoa, and the Trust Territories of the Pacific Islands.
(17) The term listed chemical means any List I chemical or List II
chemical.
(18) The term List I chemical means a chemical specifically
designated by the Administrator in Sec. 1310.02(a) of this chapter
that, in addition to legitimate uses, is used in manufacturing a
controlled substance in violation of the Act and is important to the
manufacture of a controlled substance.
(19) The term List II chemical means a chemical, other than a List
I chemical, specifically designated by the Administrator in
Sec. 1310.02(b) of this chapter that, in addition to legitimate uses,
is used in manufacturing a controlled substance in violation of the
Act.
(20) The term name means the official name, common or usual name,
chemical name, or brand name of a substance.
(21) The term person includes any individual, corporation,
government or governmental subdivision or agency, business trust,
partnership, association, or other legal entity.
(22) The term readily retrievable means that certain records are
kept by automatic data processing systems or other electronic or
mechanized recordkeeping systems in such a manner that they can be
separated out from all other records in a reasonable time and/or
records are kept on which certain items are asterisked, redlined, or in
some other manner visually identifiable apart from other items
appearing on the records.
(23) The terms register and registration refer only to registration
required and permitted by sections 303 or 1007 of the Act (21 U.S.C.
823 or 957).
(24) The term registrant means any person who is registered
pursuant to either section 303 or section 1008 of the Act (21 U.S.C.
823 or 958).
(25) The term regular customer means a person with whom the
regulated person has an established business relationship for a
specified listed chemical or chemicals that has been reported to the
Administration subject to the criteria established in
Sec. 1300.01(b)(12).
(26) The term regular importer means, with respect to a listed
chemical, a person that has an established record as an importer of
that listed chemical that is reported to the Administrator.
(27) The term regulated person means any individual, corporation,
partnership, association, or other legal entity who manufactures,
distributes, imports, or exports a listed chemical, a tableting
machine, or an encapsulating machine, or who acts as a broker or trader
for an international transaction involving a listed chemical, tableting
machine, or encapsulating machine.
(28) The term regulated transaction means:
(i) A distribution, receipt, sale, importation, or exportation of a
listed chemical, or an international transaction involving shipment of
a listed chemical, or if the Administrator establishes a threshold
amount for a specific listed chemical, a threshold amount as determined
by the Administrator, which includes a cumulative threshold amount for
multiple transactions, of a listed chemical, except that such term does
not include:
(A) A domestic lawful distribution in the usual course of business
between agents or employees of a single regulated person; in this
context, agents or employees means individuals under the direct
management and control of the regulated person;
(B) A delivery of a listed chemical to or by a common or contract
carrier for carriage in the lawful and usual course of the business of
the common or contract carrier, or to or by a warehouseman for storage
in the lawful and usual course of the business of the warehouseman,
except that if the carriage or storage is in connection with the
distribution, importation, or exportation of a listed chemical to a
third person, this paragraph does not relieve a distributor, importer,
or exporter from compliance with this part or parts 1309 and 1313 of
this chapter;
(C) Any category of transaction or any category of transaction for
a specific listed chemical or chemicals specified by regulation of the
Administrator as excluded from this definition as unnecessary for
enforcement of the Act;
(D) Any transaction in a listed chemical that is contained in a
drug that may be marketed or distributed lawfully in the United States
under the Federal Food, Drug, and Cosmetic Act unless--
(1) The drug contains ephedrine or its salts, optical isomers, or
salts of optical isomers as the only active medicinal ingredient or
contains ephedrine or its salts, optical isomers or salts of optical
isomers and therapeutically insignificant quantities of another active
medicinal ingredient. For purposes of this paragraph, the term
``therapeutically insignificant quantities'' shall apply if the product
formulation (i.e., the qualitative and quantitative composition of
active ingredients within the product) is not listed in any of the
following compendiums: American Pharmaceutical Association (Apha)
Handbook of Nonprescription Drugs; Drug Facts and Comparisons
(published by Wolters Kluwer Company); or USP DI (published by
authority of the United States Pharmacopeial Convention, Inc.); or the
product is not listed in Sec. 1310.15 of this chapter as an exempt drug
product. For drug products having formulations not found in the above
compendiums, the Administrator shall determine, pursuant to a written
request as specified in Sec. 1310.14 of this chapter, whether the
active medicinal ingredients are present in quantities considered
therapeutically significant for purposes of this paragraph; or
(2) The Administrator has determined pursuant to the criteria in
Sec. 1310.10 of this chapter that:
(i) The drug or group of drugs is being diverted to obtain the
listed chemical for use in the illicit production of a controlled
substance; and
(ii) The quantity of ephedrine or other listed chemical contained
in the drug included in the transaction or multiple transactions equals
or exceeds the threshold established for that chemical by the
Administrator;
(E) Any transaction in a chemical mixture listed in Sec. 1310.13 of
this chapter.
(ii) A distribution, importation, or exportation of a tableting
machine or encapsulating machine except that such term does not include
a domestic lawful distribution in the usual course of business between
agents and employees of a single regulated person; in this context,
agents or employees means individuals under the direct management and
control of the regulated person.
(29) The term retail distributor means a distributor whose List I
chemical activities are restricted to the sale of drug products that
are regulated as List I chemicals pursuant to
Sec. 1300.01(b)(28)(i)(D), directly to walk-in customers for personal
use.
(30) The term tableting machine means any manual, semi-automatic,
or fully automatic equipment which may be used for the compaction or
molding of powdered or granular solids, or semi-solid material, to
produce coherent solid tablets.

PART 1301--[AMENDED]

1. The authority citation for part 1301 continues to read as
follows:

Authority: 21 U.S.C. 821, 822, 823, 824, 871(b), 875, 877, 952,
956, 957, 958, unless otherwise noted.

2. Section 1301.01 is proposed to be revised to read as follows:

[[Page 8511]]

Sec. 1301.01 Scope of part 1301.

Procedures governing the registration of manufacturers,
distributors, dispensers, importers, and exporters of controlled
substances pursuant to sections 301-304 and 1007-1008 of the Act (21
U.S.C. 821-824 and 957-958) are set forth generally by those sections
and specifically by the sections of this part.
3. Section 1301.02 is proposed to be revised to read as follows:

Sec. 1301.02 Definitions.

Any term used in this part shall have the definition set forth in
section 102 of the Act (21 U.S.C. 802) or Part 1300 of this chapter.
4. As set forth in the Preamble, part 1301 is also proposed to be
amended by revising Secs. 1301.11 through 1301.52 and the undesignated
center headings and by removing Secs. 1301.53 through 1301.63 and the
undesignated center headings:

Registration

Sec. 1301.11 Persons required to register.

(a) Every person who manufactures, distributes, dispenses, imports,
or exports any controlled substance or who proposes to engage in the
manufacture, distribution, dispensing, importation or exportation of
any controlled substance shall obtain a registration unless exempted by
law or pursuant to Secs. 1301.22-1301.26. Only persons actually engaged
in such activities are required to obtain a registration; related or
affiliated persons who are not engaged in such activities are not
required to be registered. (For example, a stockholder or parent
corporation of a corporation manufacturing controlled substances is not
required to obtain a registration.)

Sec. 1301.12 Separate registrations for separate locations.

(a) A separate registration is required for each principal place of
business or professional practice at one general physical location
where controlled substances are manufactured, distributed, imported,
exported, or dispensed by a person.
(b) The following locations shall be deemed not to be places where
controlled substances are manufactured, distributed, or dispensed:
(1) A warehouse where controlled substances are stored by or on
behalf of a registered person, unless such substances are distributed
directly from such warehouse to registered locations other than the
registered location from which the substances were delivered or to
persons not required to register by virtue of subsection 302(c)(2) or
subsection 1007(b)(1)(B) of the Act (21 U.S.C. 822(c)(2) or
957(b)(1)(B));
(2) An office used by agents of a registrant where sales of
controlled substances are solicited, made, or supervised but which
neither contains such substances (other than substances for display
purposes or lawful distribution as samples only) nor serves as a
distribution point for filling sales orders; and
(3) An office used by a practitioner (who is registered at another
location) where controlled substances are prescribed but neither
administered nor otherwise dispensed as a regular part of the
professional practice of the practitioner at such office, and where no
supplies of controlled substances are maintained.

Sec. 1301.13 Application for registration; time for application;
expiration date; registration for independent activities; application
forms, fees, contents and signature; coincident activities.

(a) Any person who is required to be registered and who is not so
registered may apply for registration at any time. No person required
to be registered shall engage in any activity for which registration is
required until the application for registration is granted and a
Certificate of Registration is issued by the Administrator to such
person.
(b) Any person who is registered may apply to be reregistered not
more than 60 days before the expiration date of his/her registration,
except that a bulk manufacturer of Schedule I or II controlled
substances or an importer of Schedule I or II controlled substances may
apply to be reregistered no more than 120 days before the expiration
date of their registration.
(c) At the time a manufacturer, distributor, researcher, analytical
lab, importer, exporter or narcotic treatment program is first
registered, that business activity shall be assigned to one of twelve
groups, which shall correspond to the months of the year. The
expiration date of the registrations of all registrants within any
group will be the last date of the month designated for that group. In
assigning any of the above business activities to a group, the
Administration may select a group the expiration date of which is less
than one year from the date such business activity was registered. If
the business activity is assigned to a group which has an expiration
date less than three months from the date of which the business
activity is registered, the registration shall not expire until one
year from that expiration date; in all other cases, the registration
shall expire on the expiration date following the date on which the
business activity is registered.
(d) At the time a retail pharmacy, hospital/clinic, practitioner or
teaching institution is first registered, that business activity shall
be assigned to one of twelve groups, which shall correspond to the
months of the year. The expiration date of the registrations of all
registrants within any group will be the last day of the month
designated for that group. In assigning any of the above business
activities to a group, the Administration may select a group the
expiration date of which is not less than 28 months nor more than 39
months from the date such business activity was registered. After the
initial registration period, the registration shall expire 36 months
from the initial expiration date.
(e) Any person who is required to be registered and who is not so
registered, shall make application for registration for one of the
following groups of controlled substances activities, which are deemed
to be independent of each other. Application for each registration
shall be made on the indicated form, and shall be accompanied by the
indicated fee. Fee payments shall be made in the form of a personal,
certified, or cashier's check or money order made payable to the ``Drug
Enforcement Administration''. The application fees are not refundable.
Any person, when registered to engage in the activities described in
each subparagraph in this paragraph, shall be authorized to engage in
the coincident activities described without obtaining a registration to
engage in such coincident activities, provided that, unless
specifically exempted, he/she complies with all requirements and duties
prescribed by law for persons registered to engage in such coincident
activities. Any person who engages in more than one group of
independent activities shall obtain a separate registration for each
group of activities, except as provided in this paragraph under
coincident activities. A single registration to engage in any group of
independent activities listed below may include one or more controlled
substances listed in the schedules authorized in that group of
independent activities. A person registered to conduct research with
controlled substances listed in Schedule I may conduct research with
any substances listed in Schedule I for which he/she has filed and had
approved a research protocol.
(1)

[[Page 8512]]

--------------------------------------------------------------------------------------------------------------------------------------------------------
Application Coincident activities
Business activity Controlled substances DEA application forms fee Registration period allowed
--------------------------------------------------------------------------------------------------------------------------------------------------------
(i) Manufacturing................... Schedules I through V.. New--225............... $875 1 year................ Schedules I through V: May
Renewal--225a.......... 875 distribute that substance
or class for which
registration was issued;
may not distribute any
substance or class for
which not registered.
Schedules II through V:
May conduct chemical
analysis and preclinical
research (including
quality control analysis)
with substances listed in
those schedules for which
authorization as a
manufacturer was issued.
(ii) Distributing................... Schedules I through V.. New--225............... 438 1 year.
Renewal--225a.......... 438
(iii) Dispensing or Instructing Schedules II through V. New--224............... 210 3 years............... May conduct research and
(Includes Practitioner Hospital/ Renewal--224a.......... 210 instructional activities
Clinic, Retail Pharmacy, Teaching with those substances for
Institution). which registration was
granted, except that a mid-
level practitioner may
conduct such research only
to the extent expressly
authorized under state
statute. A pharmacist may
manufacture an aqueous or
oleaginous solution or
solid dosage form
containing a narcotic
controlled substance in
Schedule II through V in a
proportion not exceeding
20 percent of the complete
solution, compound, or
mixture.
(iv) Research or Instructing........ Schedule I............. New--225............... 70 1 year................ A researcher may
Renewal--225a.......... 70 manufacture or import the
basic class of substance
or substances for which
registration was issued,
provided that such
manufacture or import is
set forth in the protocol
required in Section
1301.18 and to distribute
such class to persons
registered or authorized
to conduct research with
such class of substance or
registered or authorized
to conduct chemical
analysis with controlled
substances.
(v) Research........................ Schedules II through V. New--225............... 70 1 year................ May conduct chemical
Renewal--225a.......... 70 analysis with controlled
substances in those
schedules for which
registration was issued;
manufacture such
substances if and to the
extent that such
manufacture is set forth
in a statement filed with
the application for
registration or
reregistration; import
such substances for
research purposes;
distribute such substances
to persons registered or
authorized to conduct
chemical analysis,
instructional activities,
or research with such
substances, and to persons
exempted from registration
pursuant to Section
1301.24, and to conduct
instructional activities
with controlled
substances.
(vi) Narcotic Treatment Program Narcotic Drugs in New--363............... 70 1 year.
(including compounder). Schedules II through V. Renewal--363a.......... 70
(vii) Importing..................... Schedules I through V.. New--225............... 438 1 year................ May distribute that
Renewal--225a.......... 438 substance or class for
which registration was
issued; may not distribute
any substance or class for
which not registered.
(viii) Exporting.................... Schedules I through V.. New--225............... 438 1 year.
Renewal--225a.......... 438
(ix) Chemical Analysis.............. Schedules I through V.. New--225............... 70 1 year................ May manufacture and import
Renewal--225a.......... 70 controlled substances for
analytical or
instructional activities;
may distribute such
substances to persons
registered or authorized
to conduct chemical
analysis, instructional
activities, or research
with such substances and
to persons exempted from
registration pursuant to
Section 1301.24; may
export such substances to
persons in other countries
performing chemical
analysis or enforcing laws
relating to controlled
substances or drugs in
those countries, and to
conduct instructional
activities with controlled
substances.
--------------------------------------------------------------------------------------------------------------------------------------------------------

[[Page 8513]]

(2) DEA Forms 224, 225, and 363 may be obtained at any area office
of the Administration or by writing to the Registration Unit, Drug
Enforcement Administration, Department of Justice, Post Office Box
28083, Central Station, Washington, DC 20005.
(3) DEA Forms 224a, 225a, and 363a will be mailed, as applicable,
to each registered person approximately 60 days before the expiration
date of his/her registration; if any registered person does not receive
such forms within 45 days before the expiration date of his/her
registration, he/she must promptly give notice of such fact and request
such forms by writing to the Registration Unit of the Administration at
the foregoing address.
(f) Each application for registration to handle any basic class of
controlled substance listed in Schedule I (except to conduct chemical
analysis with such classes), and each application for registration to
manufacture a basic class of controlled substance listed in Schedule II
shall include the Administration Controlled Substances Code Number, as
set forth in part 1308 of this chapter, for each basic class to be
covered by such registration.
(g) Each application for registration to import or export
controlled substances shall include the Administration Controlled
Substances Code Number, as set forth in part 1308 of this chapter, for
each controlled substance whose importation or exportation is to be
authorized by such registration. Registration as an importer or
exporter shall not entitle a registrant to import or export any
controlled substance not specified in such registration.
(h) Each application for registration to conduct research with any
basic class of controlled substance listed in Schedule II shall include
the Administration Controlled Substances Code Number, as set forth in
part 1308 of this chapter, for each such basic class to be manufactured
or imported as a coincident activity of that registration. A statement
listing the quantity of each such basic class or controlled substance
to be imported or manufactured during the registration period for which
application is being made shall be included with each such application.
For purposes of this paragraph only, manufacturing is defined as the
production of a controlled substance by synthesis, extraction or by
agricultural/horticultural means.
(i) Each application shall include all information called for in
the form, unless the item is not applicable, in which case this fact
shall be indicated.
(j) Each application, attachment, or other document filed as part
of an application, shall be signed by the applicant, if an individual;
by a partner of the applicant, if a partnership; or by an officer of
the applicant, if a corporation, corporate division, association, trust
or other entity. An applicant may authorize one or more individuals,
who would not otherwise be authorized to do so, to sign applications
for the applicant by filing with the Registration Unit of the
Administration a power of attorney for each such individual. The power
of attorney shall be signed by a person who is authorized to sign
applications under this paragraph and shall contain the signature of
the individual being authorized to sign applications. The power of
attorney shall be valid until revoked by the applicant.

Sec. 1301.14 Filing of application; acceptance for filing; defective
applications.

(a) All applications for registration shall be submitted for filing
to the Registration Unit, Drug Enforcement Administration, Department
of Justice, Post Office Box 28083, Central Station, Washington, DC
20005. The appropriate registration fee and any required attachments
must accompany the application.
(b) Any person required to obtain more than one registration may
submit all applications in one package. Each application must be
complete and should not refer to any accompanying application for
required information.
(c) Applications submitted for filing are dated upon receipt. If
found to be complete, the application will be accepted for filing.
Applications failing to comply with the requirements of this part will
not generally be accepted for filing. In the case of minor defects as
to completeness, the Administrator may accept the application for
filing with a request to the applicant for additional information. A
defective application will be returned to the applicant within 10 days
following its receipt with a statement of the reason for not accepting
the application for filing. A defective application may be corrected
and resubmitted for filing at any time; the Administrator shall accept
for filing any application upon resubmission by the applicant, whether
complete or not.
(d) Accepting an application for filing does not preclude any
subsequent request for additional information pursuant to Sec. 1301.15
and has no bearing on whether the application will be granted.

Sec. 1301.15 Additional Information.

The Administrator may require an applicant to submit such documents
or written statements of fact relevant to the application as he/she
deems necessary to determine whether the application should be granted.
The failure of the applicant to provide such documents or statements
within a reasonable time after being requested to do so shall be deemed
to be a waiver by the applicant of an opportunity to present such
documents or facts for consideration by the Administrator in granting
or denying the application.

Sec. 1301.16 Amendments to and withdrawal of applications.

(a) An application may be amended or withdrawn without permission
of the Administrator at any time before the date on which the applicant
receives an order to show cause pursuant to Sec. 1301.37. An
application may be amended or withdrawn with permission of the
Administrator at any time where good cause is shown by the applicant or
where the amendment or withdrawal is in the public interest.
(b) After an application has been accepted for filing, the request
by the applicant that it be returned or the failure of the applicant to
respond to official correspondence regarding the application, when sent
by registered or certified mail, return receipt requested, shall be
deemed to be a withdrawal of the application.

Sec. 1301.17 Special procedures for certain applications.

(a) If, at the time of application for registration of a new
pharmacy, the pharmacy has been issued a license from the appropriate
State licensing agency, the applicant may include with his/her
application an affidavit as to the existence of the State license in
the following form:

Affidavit for New Pharmacy
I, __________, the ________________________ (Title of officer,
official, partner, or other position) of ________________________
(Corporation, partnership, or sole proprietor), doing business as
________________ (Store name) at ________________ (Number and
Street), ________________ (City) ________________ (State)
________________ (Zip code), hereby certify that said store was
issued a pharmacy permit No. ________ by the
________________________ (Board of Pharmacy or Licensing Agency) of
the State of ____________________ on ____________ (Date).
This statement is submitted in order to obtain a Drug
Enforcement Administration registration number. I understand that if
any information is false, the Administration may immediately suspend
the registration for this store and commence proceedings to revoke
under 21 U.S.C. 824(a) because of the danger to public health and
safety. I further understand that any false information

[[Page 8514]]
contained in this affidavit may subject me personally and the above-
named corporation/partnership/business to prosecution under 21
U.S.C. 843, the penalties for conviction of which include
imprisonment for up to 4 years, a fine of not more than $30,000 or
both.

-----------------------------------------------------------------------

Signature (Person who signs Application for Registration) State of
____________

County of____________________------------------------------------------

Subscribed to and sworn before me this __________ day of
______________, 19____.

-----------------------------------------------------------------------

Notary Public
(b) Whenever the ownership of a pharmacy is being transferred from
one person to another, if the transferee owns at least one other
pharmacy licensed in the same State as the one the ownership of which
is being transferred, the transferee may apply for registration prior
to the date of transfer. The Administrator may register the applicant
and authorize him to obtain controlled substances at the time of
transfer. Such registration shall not authorize the transferee to
dispense controlled substances until the pharmacy has been issued a
valid State license. The transferee shall include with his/her
application the following affidavit:

Affidavit for Transfer of Pharmacy

I, ________________, the ________________________ (Title of
officer, official, partner or other position) of
________________________ (Corporation, partnership, or sole
proprietor), doing business as ________________ (Store name) hereby
certify:
(1) That said company was issued a pharmacy permit No. ________
by the ________________________ (Board of Pharmacy of Licensing
Agency) of the State of ________________ and a DEA Registration
Number __________ for a pharmacy located at ____________________
(Number and Street) ________________ (City) ____________________
(State) ________________ (Zip Code); and
(2) That said company is acquiring the pharmacy business of
________________ (Name of Seller) doing business as ________________
with DEA Registration Number __________ on or about ________________
(Date of Transfer) and that said company has applied (or will apply
on ________________ (Date) for a pharmacy permit from the board of
pharmacy (or licensing agency) of the State of ________________ to
do business as __________ (Store name) at ________________ (Number
and Street) ________________ (City) ________________ (State)
________________ (Zip Code).
This statement is submitted in order to obtain a Drug
Enforcement Administration registration number.
I understand that if a DEA registration number is issued, the
pharmacy may acquire controlled substances but may not dispense them
until a pharmacy permit or license is issued by the State board of
pharmacy or licensing agency.
I understand that if any information is false, the
Administration may immediately suspend the registration for this
store and commence proceedings to revoke under 21 U.S.C. 824(a)
because of the danger to public health and safety. I further
understand that any false information contained in this affidavit
may subject me personally to prosecution under 21 U.S.C. 843, the
penalties for conviction of which include imprisonment for up to 4
years, a fine of not more than $30,000 or both.

-----------------------------------------------------------------------

Signature (Person who signs Application for Registration)

State of---------------------------------------------------------------

County of--------------------------------------------------------------

Subscribed to and sworn before me this ____________ day of
________________, 19____.

-----------------------------------------------------------------------

Notary Public

(c) The Administrator shall follow the normal procedures for
approving an application to verify the statements in the affidavit. If
the statements prove to be false, the Administrator may revoke the
registration on the basis of section 304(a)(1) of the Act (21 U.S.C.
824(a)(1)) and suspend the registration immediately by pending
revocation on the basis of section 304(d) of the Act (21 U.S.C.
824(d)). At the same time, the Administrator may seize and place under
seal all controlled substances possessed by the applicant under section
304(f) of the Act (21 U.S.C. 824(f)). Intentional misuse of the
affidavit procedure may subject the applicant to prosecution for fraud
under section 403(a)(4) of the Act (21 U.S.C. 843(a)(4)), and obtaining
controlled substances under a registration fraudulently gotten may
subject the applicant to prosecution under section 403(a)(3) of the Act
(21 U.S.C. 843(a)(3)). The penalties for conviction of either offense
include imprisonment for up to 4 years, a fine not exceeding $30,000 or
both.

Sec. 1301.18 Research protocols.

(a) A protocol to conduct research with controlled substances
listed in Schedule I shall be in the following form and contain the
following information where applicable:
(1) Investigator:
(i) Name, address, and DEA registration number; if any.
(ii) Institutional affiliation.
(iii) Qualifications, including a curriculum vitae and an
appropriate bibliography (list of publications).
(2) Research project:
(i) Title of project.
(ii) Statement of the purpose.
(iii) Name of the controlled substances or substances involved and
the amount of each needed.
(iv) Description of the research to be conducted, including the
number and species of research subjects, the dosage to be administered,
the route and method of administration, and the duration of the
project.
(v) Location where the research will be conducted.
(vi) Statement of the security provisions for storing the
controlled substances (in accordance with Sec. 1301.75) and for
dispensing the controlled substances in order to prevent diversion.
(vii) If the investigator desires to manufacture or import any
controlled substance listed in paragraph (a)(2)(iii) of this section, a
statement of the quantity to be manufactured or imported and the
sources of the chemicals to be used or the substance to be imported.
(3) Authority:
(i) Institutional approval.
(ii) Approval of a Human Research Committee for human studies.
(iii) Indication of an approved active Notice of Claimed
Investigational Exemption for a New Drug (number).
(iv) Indication of an approved funded grant (number), if any.
(b) In the case of a clinical investigation with controlled
substances listed in Schedule I, the applicant shall submit three
copies of a Notice of Claimed Investigational Exemption for a New Drug
(IND) together with a statement of the security provisions (as
prescribed in paragraph (a)(2)(v) of this section for a research
protocol) to, and have such submission approved by, the Food and Drug
Administration as required in 21 U.S.C. 355(i) and Sec. 130.3 of this
title. Submission of this Notice and statement to the Food and Drug
Administration shall be in lieu of a research protocol to the
Administration as required in paragraph (a) of this section. The
applicant, when applying for registration with the Administration,
shall indicate that such notice has been submitted to the Food and Drug
Administration by submitting to the Administration with his/her DEA
Form 225 three copies of the following certificate:

I hereby certify that on ________ (Date), pursuant to 21 U.S.C.
355(i) and 21 CFR 130.3, I, __________ __________ __________ (Name
and Address of IND Sponsor) submitted a Notice of Claimed
Investigational Exemption for a New Drug (IND) to the Food and Drug
Administration for:

[[Page 8515]]

----------------------------------------------------------------------
(Name of Investigational Drug).
____________ (Date)

----------------------------------------------------------------------
(Signature of Applicant).

(c) In the event that the registrant desires to increase the
quantity of a controlled substance used for an approved research
project, he/she shall submit a request to the Registration Unit, Drug
Enforcement Administration, Post Office Box 28083, Central Station,
Washington, DC 20005, by registered mail, return receipt requested. The
request shall contain the following information: DEA registration
number; name of the controlled substance or substances and the quantity
of each authorized in the approved protocol; and the additional
quantity of each desired. Upon return of the receipt, the registrant
shall be authorized to purchase the additional quantity of the
controlled substance or substances specified in the request. The
Administration shall review the letter and forward it to the Food and
Drug Administration together with the Administration comments. The Food
and Drug Administration shall approve or deny the request as an
amendment to the protocol and so notify the registrant. Approval of the
letter by the Food and Drug Administration shall authorize the
registrant to use the additional quantity of the controlled substance
in the research project.
(d) In the event the registrant desires to conduct research beyond
the variations provided in the registrant's approved protocol
(excluding any increase in the quantity of the controlled substance
requested for his/her research project as outlined in paragraph (c) of
this section), he/she shall submit three copies of a supplemental
protocol in accordance with paragraph (a) of this section describing
the new research and omitting information in the supplemental protocol
which has been stated in the original protocol. Supplemental protocols
shall be processed and approved or denied in the same manner as
original research protocols.

Exceptions To Registration and Fees

Sec. 1301.21 Exemption from fees.

(a) The Administrator shall exempt from payment of an application
fee for registration or reregistration:
(1) Any hospital or other institution which is operated by an
agency of the United States (including the U.S. Army, Navy, Marine
Corps., Air Force, and Coast Guard), of any State, or any political
subdivision or agency thereof.
(2) Any individual practitioner who is required to obtain an
individual registration in order to carry out his or her duties as an
official of an agency of the United States (including the U.S. Army,
Navy, Marine Corps., Air Force, and Coast Guard), of any State, or any
political subdivision or agency thereof.
(b) In order to claim exemption from payment of a registration or
reregistration application fee, the registrant shall have completed the
certification on the appropriate application form, wherein the
registrant's superior (if the registrant is an individual) or officer
(if the registrant is an agency) certifies to the status and address of
the registrant and to the authority of the registrant to acquire,
possess, or handle controlled substances.
(c) Exemption from payment of a registration or reregistration
application fee does not relieve the registrant of any other
requirements or duties prescribed by law.

Sec. 1301.22 Exemption of agents and employees; affiliated
practitioners.

(a) The requirement of registration is waived for any agent or
employee of a person who is registered to engage in any group of
independent activities, if such agent or employee is acting in the
usual course of his/her business or employment.
(b) An individual practitioner who is an agent or employee of
another practitioner (other than a mid-level practitioner) registered
to dispense controlled substances may, when acting in the normal course
of business or employment, administer or dispense (other than by
issuance of prescription) controlled substances if and to the extent
that such individual practitioner is authorized or permitted to do so
by the jurisdiction in which he or she practices, under the
registration of the employer or principal practitioner in lieu of being
registered him/herself.
(c) An individual practitioner who is an agent or employee of a
hospital or other institution may, when acting in the normal course of
business or employment, administer, dispense, or prescribe controlled
substances under the registration of the hospital or other institution
which is registered in lieu of being registered him/herself, provided
that:
(1) Such dispensing, administering or prescribing is done in the
usual course of his/her professional practice;
(2) Such individual practitioner is authorized or permitted to do
so by the jurisdiction in which he/she is practicing;
(3) The hospital or other institution by whom he/she is employed
has verified that the individual practitioner is so permitted to
dispense, administer, or prescribe drugs within the jurisdiction;
(4) Such individual practitioner is acting only within the scope of
his/her employment in the hospital or institution;
(5) The hospital or other institution authorizes the individual
practitioner to administer, dispense or prescribe under the hospital
registration and designates a specific internal code number for each
individual practitioner so authorized. The code number shall consist of
numbers, letters, or a combination thereof and shall be a suffix to the
institution's DEA registration number, preceded by a hyphen (e.g., APO
123456-10 or APO123456-A12); and
(6) A current list of internal codes and the corresponding
individual practitioners is kept by the hospital or other institution
and is made available at all times to other registrants and law
enforcement agencies upon request for the purpose of verifying the
authority of the prescribing individual practitioner.

Sec. 1301.23 Exemption of certain military and other personnel.

(a) The requirement of registration is waived for any official of
the U.S. Army, Navy, Marine Corps, Air Force, Coast Guard, Public
Health Service, or Bureau of Prisons who is authorized to prescribe,
dispense, or administer, but not to procure or purchase, controlled
substances in the course of his/her official duties. Such officials
shall follow procedures set forth in part 1306 of this chapter
regarding prescriptions, but shall state the branch of service or
agency (e.g., ``U.S. Army'' or ``Public Health Service'') and the
service identification number of the issuing official in lieu of the
registration number required on prescription forms. The service
identification number for a Public Health Service employee is his/her
Social Security identification number.
(b) The requirement of registration is waived for any official or
agency of the U.S. Army, Navy, Marine Corps, Air Force, Coast Guard, or
Public Health Service who or which is authorized to import or export
controlled substances in the course of his/her official duties.
(c) If any official exempted by this section also engages as a
private individual in any activity or group of activities for which
registration is required, such official shall obtain a registration for
such private activities.

[[Page 8516]]

Sec. 1301.24 Exemption of law enforcement officials.

(a) The requirement of registration is waived for the following
persons in the circumstances described in this section:
(1) Any officer or employee of the Administration, any officer of
the U.S. Customs Service, any officer or employee of the United States
Food and Drug Administration, and any other Federal officer who is
lawfully engaged in the enforcement of any Federal law relating to
controlled substances, drugs or customs, and is duly authorized to
possess or to import or export controlled substances in the course of
his/her official duties; and
(2) Any officer or employee of any State, or any political
subdivision or agency thereof, who is engaged in the enforcement of any
State or local law relating to controlled substances and is duly
authorized to possess controlled substances in the course of his/her
official duties.
(b) Any official exempted by this section may, when acting in the
course of his/her official duties, procure any controlled substance in
the course of an inspection, in accordance with Sec. 1316.03(d) of this
chapter, or in the course of any criminal investigation involving the
person from whom the substance was procured, and may possess any
controlled substance and distribute any such substance to any other
official who is also exempted by this section and acting in the course
of his/her official duties.
(c) In order to enable law enforcement agency laboratories,
including laboratories of the Administration, to obtain and transfer
controlled substances for use as standards in chemical analysis, such
laboratories shall obtain annually a registration to conduct chemical
analysis. Such laboratories shall be exempted from payment of a fee for
registration. Laboratory personnel, when acting in the scope of their
official duties, are deemed to be officials exempted by this section
and within the activity described in section 515(d) of the Act (21
U.S.C. 885(d)). For purposes of this paragraph, laboratory activities
shall not include field or other preliminary chemical tests by
officials exempted by this section.
(d) In addition to the activities authorized under a registration
to conduct chemical analysis pursuant to Sec. 1301.13(e)(1)(ix),
laboratories of the Administration shall be authorized to manufacture
or import controlled substances for any lawful purpose, to distribute
or export such substances to any person, and to import and export such
substances in emergencies without regard to the requirements of part
1312 of this chapter if a report concerning the importation or
exportation is made to the Drug Operations Section of the
Administration within 30 days of such importation or exportation.

Sec. 1301.25 Registration regarding ocean vessels, aircraft, and other
entities.

(a) If acquired by and dispensed under the general supervision of a
medical officer described in paragraph (b) of this section, or the
master or first officer of the vessel under the circumstances described
in paragraph (d) of this section, controlled substances may be held for
stocking, be maintained in, and dispensed from medicine chests, first
aid packets, or dispensaries:
(1) On board any vessel engaged in international trade or in trade
between ports of the United States and any merchant vessel belonging to
the U.S. Government;
(2) On board any aircraft operated by an air carrier under a
certificate of permit issued pursuant to the Federal Aviation Act of
1958 (49 U.S.C. 1301); and
(3) In any other entity of fixed or transient location approved by
the Administrator as appropriate for application of this section (e.g.,
emergency kits at field sites of an industrial firm).
(b) A medical officer shall be:
(1) Licensed in a state as a physician;
(2) Employed by the owner or operator of the vessel, aircraft or
other entity; and
(3) Registered under the Act at either of the following locations:
(i) The principal office of the owner or operator of the vessel,
aircraft or other entity or
(ii) At any other location provided that the name, address,
registration number and expiration date as they appear on his/her
Certificate of Registration (DEA Form 223) for this location are
maintained for inspection at said principal office in a readily
retrievable manner.
(c) A registered medical officer may serve as medical officer for
more than one vessel, aircraft, or other entity under a single
registration, unless he/she serves as medical officer for more than one
owner or operator, in which case he/she shall either maintain a
separate registration at the location of the principal office of each
such owner or operator or utilize one or more registrations pursuant to
paragraph (b)(3)(ii) of this section.
(d) If no medical officer is employed by the owner or operator of a
vessel, or in the event such medical officer is not accessible and the
acquisition of controlled substances is required, the master or first
officer of the vessel, who shall not be registered under the Act, may
purchase controlled substances from a registered manufacturer or
distributor, or from an authorized pharmacy as described in paragraph
(f) of this section, by following the procedure outlined below:
(1) The master or first officer of the vessel must personally
appear at the vendor's place of business, present proper identification
(e.g., Seaman's photographic identification card) and a written
requisition for the controlled substances.
(2) The written requisition must be on the vessel's official
stationery or purchase order form and must include the name and address
of the vendor, the name of the controlled substance, description of the
controlled substance (dosage form, strength and number or volume per
container) number of containers ordered, the name of the vessel, the
vessel's official number and country of registry, the owner or operator
of the vessel, the port at which the vessel is located, signature of
the vessel's officer who is ordering the controlled substances and the
date of the requisition.
(3) The vendor may, after verifying the identification of the
vessel's officer requisitioning the controlled substances, deliver the
control substances to that officer. The transaction shall be
documented, in triplicate, on a record of sale in a format similar to
that outlined in paragraph (d)(4) of this section. The vessel's
requisition shall be attached to copy 1 of the record of sale and filed
with the controlled substances records of the vendor, copy 2 of the
record of sale shall be furnished to the officer of the vessel and
retained aboard the vessel, copy 3 of the record of sale shall be
forwarded to the nearest DEA Division Office within 15 days after the
end of the month in which the sale is made.
(4) The vendor's record of sale should be similar to, and must
include all the information contained in, the below listed format.

Sale of Controlled Substances to Vessels

(Name of registrant)
----------------------------------------------------------------------

(Address of registrant)
----------------------------------------------------------------------
(DEA registration number)
----------------------------------------------------------------------

* * * TABLE START * * *

[[Page 8517]]

----------------------------------------------------------------------------------------------------------------
Number of
Line No. packages Size of Name of Packages Date
ordered packages product distributed distributed
----------------------------------------------------------------------------------------------------------------
1............................... .............. .............. .............. .............. ..............
2............................... .............. .............. .............. .............. ..............
3............................... .............. .............. .............. .............. ..............
----------------------------------------------------------------------------------------------------------------
FOOTNOTE: Line numbers may be continued according to needs of the vendor.

* * * TABLE END * * *

Number of lines completed
----------------------------------------------------------------------

Name of vessel
----------------------------------------------------------------------

Vessel's official number
----------------------------------------------------------------------

Vessel's country of registry
----------------------------------------------------------------------

Owner or operator of the vessel
----------------------------------------------------------------------

Name and title of vessel's officer who presented the requisition
----------------------------------------------------------------------
Signature of vessel's officer who presented the requisition
----------------------------------------------------------------------

(e) Any medical officer described in paragraph (b) of this section
shall, in addition to complying with all requirements and duties
prescribed for registrants generally, prepare an annual report as of
the date on which his/her registration expires, which shall give in
detail an accounting for each vessel, aircraft, or other entity, and a
summary accounting for all vessels, aircraft, or other entities under
his/her supervision for all controlled substances purchased, dispensed
or disposed of during the year. The medical officer shall maintain this
report with other records required to be kept under the Act and, upon
request, deliver a copy of the report to the Administration. The
medical officer need not be present when controlled substances are
dispensed, if the person who actually dispensed the controlled
substances is responsible to the medical officer to justify his/her
actions.
(f) Any registered pharmacy which wishes to distribute controlled
substances pursuant to this section shall be authorized to do so,
provided that:
(1) The registered pharmacy notifies the nearest Division Office of
the Administration of its intention to so distribute controlled
substances prior to the initiation of such activity. This notification
shall be by registered mail and shall contain the name, address, and
registration number of the pharmacy as well as the date upon which such
activity will commence; and
(2) Such activity is authorized by state law; and
(3) The total number of dosage units of all controlled substances
distributed by the pharmacy during any calendar year in which the
pharmacy is registered to dispense does not exceed the limitations
imposed upon such distribution by Sec. 1307.11(a) (4) and (b) of this
chapter.
(g) Owners or operators of vessels, aircraft, or other entities
described in this section shall not be deemed to possess or dispense
any controlled substance acquired, stored and dispensed in accordance
with this section. Additionally, owners or operators of vessels,
aircraft, or other entities described in this section or in Article 32
of the Single Convention on Narcotic Drugs, 1961, or in Article 14 of
the Convention on Psychotropic Substances, 1971, shall not be deemed to
import or export any controlled substances purchased and stored in
accordance with that section or applicable article.
(h) The Master of a vessel shall prepare a report for each calendar
year which shall give in detail an accounting for all controlled
substances purchased, dispensed, or disposed of during the year. The
Master shall file this report with the medical officer employed by the
owner or operator of his/her vessel, if any, or, if not, he/she shall
maintain this report with other records required to be kept under the
Act and, upon request, deliver a copy of the report to the
Administration.
(i) Controlled substances acquired and possessed in accordance with
this section shall not be distributed to persons not under the general
supervision of the medical officer employed by the owner or operator of
the vessel, aircraft, or other entity, except in accordance with
Sec. 1307.21 of this chapter.
Sec. 1301.26 Exemptions from import or export requirements for
personal medical use.
Any individual who has in his/her possession a controlled substance
listed in schedules II, III, IV, or V, which he/she has lawfully
obtained for his/her personal medical use, or for administration to an
animal accompanying him/her, may enter or depart the United States with
such substance notwithstanding sections 1002-1005 of the Act (21 U.S.C.
952-955), providing the following conditions are met:
(a) The controlled substance is in the original container in which
it was dispensed to the individual; and
(b) The individual makes a declaration to an appropriate official
of the U.S. Customs Service stating:
(1) That the controlled substance is possessed for his/her personal
use, or for an animal accompanying him/her; and
(2) The trade or chemical name and the symbol designating the
schedule of the controlled substance if it appears on the container
label, or, if such name does not appear on the label, the name and
address of the pharmacy or practitioner who dispensed the substance and
the prescription number, if any.
Action on Applications for Registration: Revocation or Suspension of
Registration
Sec. 1301.31 Administrative review generally.
The Administrator may inspect, or cause to be inspected, the
establishment of an applicant or registrant, pursuant to subpart A of
part 1316 of this chapter. The Administrator shall review, the
application for registration and other information gathered by the
Administrator regarding an applicant in order to determine whether the
applicable standards of section 303 of the Act (21 U.S.C. 823) or
section 1008 (21 U.S.C. 958) have been met by the applicant.

Sec. 1301.32
Action on applications for research in Schedule I substances.
(a) In the case of an application for registration to conduct
research with controlled substances listed in Schedule I, the
Administrator shall process the application and protocol and forward a
copy of each to the Secretary within 7 days after receipt. The
Secretary shall determine the qualifications and competency of the
applicant, as well as the merits of the protocol (and shall notify the
Administrator of his/her determination) within 21 days after receipt of
the application and complete protocol, except that in the case of a
clinical investigation, the Secretary shall have 30 days to make such
determination and notify the Administrator. The Secretary, in
determining the merits of the protocol,

[[Page 8518]]

shall consult with the Administrator as to effective procedures to
safeguard adequately against diversion of such controlled substances
from legitimate medical or scientific use.
(b) An applicant whose protocol is defective shall be notified by
the Secretary within 21 days after receipt of such protocol from the
Administrator (or in the case of a clinical investigation within 30
days), and he/she shall be requested to correct the existing defects
before consideration shall be given to his/her submission.
(c) If the Secretary determines the applicant qualified and
competent and the research protocol meritorious, he/she shall notify
the Administrator in writing of such determination. The Administrator
shall issue a certificate of registration within 10 days after receipt
of this notice, unless he/she determines that the certificate of
registration should be denied on a ground specified in section 304(a)
of the Act (21 U.S.C. 824(a)). In the case of a supplemental protocol,
a replacement certificate of registration shall be issued by the
Administrator.
(d) If the Secretary determines that the protocol is not
meritorious and/or the applicant is not qualified or competent, he/she
shall notify the Administrator in writing setting forth the reasons for
such determination. If the Administrator determines that grounds exist
for the denial of the application, he/she shall within 10 days issue an
order to show cause pursuant to Sec. 1301.37 and, if requested by the
applicant, hold a hearing on the application pursuant to Sec. 1301.41.
If the grounds for denial of the application include a determination by
the Secretary, the Secretary or his duly authorized agent shall furnish
testimony and documents pertaining to his determination at such
hearing.
(e) Supplemental protocols will be processed in the same manner as
original research protocols. If the processing of an application or
research protocol is delayed beyond the time limits imposed by this
section, the applicant shall be so notified in writing.

Sec. 1301.33 Application for bulk manufacture of Schedule I and II
substances.

(a) In the case of an application for registration or
reregistration to manufacture in bulk a basic class of controlled
substance listed in Schedule I or II, the Administrator shall, upon the
filing of such application, publish in the Federal Register a notice
naming the applicant and stating that such applicant has applied to be
registered as a bulk manufacturer of a basic class of narcotic or
nonnarcotic controlled substance, which class shall be identified. A
copy of said notice shall be mailed simultaneously to each person
registered as a bulk manufacturer of that basic class and to any other
applicant therefor. Any such person may, within 60 days from the date
of publication of the notice in the Federal Register, file with the
Administrator written comments on or objections to the issuance of the
proposed registration.
(b) In order to provide adequate competition, the Administrator
shall not be required to limit the number of manufacturers in any basic
class to a number less than that consistent with maintenance of
effective controls against diversion solely because a smaller number is
capable of producing an adequate and uninterrupted supply.
(c) This section shall not apply to the manufacture of basic
classes of controlled substances listed in Schedules I or II as an
incident to research or chemical analysis as authorized in
Sec. 01.13(e)(1).

Sec. 1301.34 Application for importation of Schedule I and II
substances.

(a) In the case of an application for registration or
reregistration to import a controlled substance listed in Schedule I or
II, under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)), the Administrator shall, upon the filing of such
application, publish in the Federal Register a notice naming the
applicant and stating that such applicant has applied to be registered
as an importer of a Schedule I or II controlled substance, which
substance shall be identified. A copy of said notice shall be mailed
simultaneously to each person registered as a bulk manufacturer of that
controlled substance and to any other applicant therefor. Any such
person may, within 30 days from the date of publication of the notice
in the Federal Register, file written comments on or objections to the
issuance of the proposed registration, and may, at the same time, file
a written request for a hearing on the application pursuant to
Sec. 1301.43. If a hearing is requested, the Administrator shall hold a
hearing on the application in accordance with Sec. 1301.41. Notice of
the hearing shall be published in the Federal Register, and shall be
mailed simultaneously to the applicant and to all persons to whom
notice of the application was mailed. Any such person may participate
in the hearing by filing a notice of appearance in accordance with
Sec. 1301.43 of this chapter. Notice of the hearing shall contain a
summary of all comments and objections filed regarding the application
and shall state the time and place for the hearing, which shall not be
less than 30 days after the date of publication of such notice in the
Federal Register. A hearing pursuant to this section may be
consolidated with a hearing held pursuant to Secs. 1301.35 or 1301.36
of this part.
(b) The Administrator shall register an applicant to import a
controlled substance listed in Schedule I or II if he/she determines
that such registration is consistent with the public interest and with
U.S. obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. In determining the public interest,
the following factors shall be considered:
(1) Maintenance of effective controls against diversion of
particular controlled substances and any controlled substance in
Schedule I or II compounded therefrom into other than legitimate
medical, scientific research, or industrial channels, by limiting the
importation and bulk manufacture of such controlled substances to a
number of establishments which can produce an adequate and
uninterrupted supply of these substances under adequately competitive
conditions for legitimate medical, scientific, research, and industrial
purposes;
(2) Compliance with applicable State and local law;
(3) Promotion of technical advances in the art of manufacturing
these substances and the development of new substances;
(4) Prior conviction record of applicant under Federal and State
laws relating to the manufacture, distribution, or dispensing of such
substances;
(5) Past experience in the manufacture of controlled substances,
and the existence in the establishment of effective control against
diversion;
(6) That the applicant will be permitted to import only:
(i) Such amounts of crude opium, poppy straw, concentrate of poppy
straw, and coca leaves as the Administrator finds to be necessary to
provide for medical, scientific, or other legitimate purposes; or
(ii) Such amounts of any controlled substances listed in Schedule I
or II as the Administrator shall find to be necessary to provide for
the medical, scientific, or other legitimate needs of the United States
during an emergency in which domestic supplies of such substances are
found by the Administrator to be inadequate; or
(iii) Such amounts of any controlled substance listed in Schedule I
or II as the Administrator shall find to be necessary to provide for
the medical, scientific, or other legitimate needs of the United States
in any case in which

[[Page 8519]]
the Administrator finds that competition among domestic manufacturers
of the controlled substance is inadequate and will not be rendered
adequate by the registration of additional manufacturers under section
303 of the Act (21 U.S.C. 823); or
(iv) Such limited quantities of any controlled substance listed in
Schedule I or II as the Administrator shall find to be necessary for
scientific, analytical or research uses; and
(7) Such other factors as may be relevant to and consistent with
the public health and safety.
(c) In determining whether the applicant can and will maintain
effective controls against diversion within the meaning of paragraph
(b) of this section, the Administrator shall consider among other
factors:
(1) Compliance with the security requirements set forth in
Secs. 1301.71-1301.76 and
(2) Employment of security procedures to guard against in-transit
losses within and without the jurisdiction of the United States.
(d) In determining whether competition among the domestic
manufacturers of a controlled substance is adequate within the meaning
of paragraphs (b)(1) and (b)(6)(iii) of this section, as well as
section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)), the
Administrator shall consider:
(1) The extent of price rigidity in the light of changes in:
(i) Raw materials and other costs and
(ii) Conditions of supply and demand;
(2) The extent of service and quality competition among the
domestic manufacturers for shares of the domestic market including:
(i) Shifts in market shares and
(ii) Shifts in individual customers among domestic manufacturers;
(3) The existence of substantial differentials between domestic
prices and the higher of prices generally prevailing in foreign markets
or the prices at which the applicant for registration to import is
committed to undertake to provide such products in the domestic market
in conformity with the Act. In determining the existence of substantial
differentials hereunder, appropriate consideration should be given to
any additional costs imposed on domestic manufacturers by the
requirements of the Act and such other cost-related and other factors
as the Administrator may deem relevant. In no event shall an importer's
offering prices in the United States be considered if they are lower
than those prevailing in the foreign market or markets from which the
importer is obtaining his/her supply;
(4) The existence of competitive restraints imposed upon domestic
manufacturers by governmental regulations; and
(5) Such other factors as may be relevant to the determinations
required under this paragraph.
(e) In considering the scope of the domestic market, consideration
shall be given to substitute products which are reasonably
interchangeable in terms of price, quality and use.
(f) The fact that the number of existing manufacturers is small
shall not demonstrate, in and of itself, that adequate competition
among them does not exist.

Sec. 1301.35 Certificate of registration; denial of registration.

(a) The Administrator shall issue a Certificate of Registration
(DEA Form 223) to an applicant if the issuance of registration or
reregistration is required under the applicable provisions of sections
303 or 1008 of the Act (21 U.S.C. 823 and 958). In the event that the
issuance of registration or reregistration is not required, the
Administrator shall deny the application. Before denying any
application, the Administrator shall issue an order to show cause
pursuant to Sec. 1301.37 and, if requested by the applicant, shall hold
a hearing on the application pursuant to Sec. 1301.41.
(b) If a hearing is requested by an applicant for registration or
reregistration to manufacture in bulk a basic class of controlled
substance listed in Schedule I or II, notice that a hearing has been
requested shall be published in the Federal Register and shall be
mailed simultaneously to the applicant and to all persons to whom
notice of the application was mailed. Any person entitled to file
comments or objections to the issuance of the proposed registration
pursuant to Sec. 1301.33(a) may participate in the hearing by filing
notice of appearance in accordance with Sec. 1301.43. Such persons
shall have 30 days to file a notice of appearance after the date of
publication of the notice of a request for a hearing in the Federal
Register.
(c) The Certificate of Registration (DEA Form 223) shall contain
the name, address, and registration number of the registrant, the
activity authorized by the registration, the schedules and/or
Administration Controlled Substances Code Number (as set forth in part
1308 of this chapter) of the controlled substances which the registrant
is authorized to handle, the amount of fee paid (or exemption), and the
expiration date of the registration. The registrant shall maintain the
certificate of registration at the registered location in a readily
retrievable manner and shall permit inspection of the certificate by
any official, agent or employee of the Administration or of any
Federal, State, or local agency engaged in enforcement of laws relating
to controlled substances.

Sec. 1301.36 Suspension or revocation of registration; suspension of
registration pending final order; extension of registration pending
final order.

(a) For any registration issued under section 303 of the Act (21
U.S.C. 823), the Administrator may:
(1) Suspend the registration pursuant to section 304(a) of the Act
(21 U.S.C. 824(a)) for any period of time.
(2) Revoke the registration pursuant to section 304(a) of the Act
(21 U.S.C. 824(a)).
(b) For any registration issued under section 1008 of the Act (21
U.S.C. 958), the Administrator may:
(1) Suspend the registration pursuant to section 1008(d) of the Act
(21 U.S.C. 958(d)) for any period of time.
(2) Revoke the registration pursuant to section 1008(d) of the Act
(21 U.S.C. 958(d)) if he/she determines that such registration is
inconsistent with the public interest as defined in section 1008 or
with the United States obligations under international treaties,
conventions, or protocols in effect on October 12, 1984.
(c) The Administrator may limit the revocation or suspension of a
registration to the particular controlled substance, or substances,
with respect to which grounds for revocation or suspension exist.
(d) Before revoking or suspending any registration, the
Administrator shall issue an order to show cause pursuant to
Sec. 1301.37 and, if requested by the registrant, shall hold a hearing
pursuant to Sec. 13.01.41.
(e) The Administrator may suspend any registration simultaneously
with or at any time subsequent to the service upon the registrant of an
order to show cause why such registration should not be revoked or
suspended, in any case where he/she finds that there is an imminent
danger to the public health or safety. If the Administrator so
suspends, he/she shall serve with the order to show cause pursuant to
Sec. 1301.37 an order of immediate suspension which shall contain a
statement of his findings regarding the danger to public health or
safety.
(f) Upon service of the order of the Administrator suspending or
revoking registration, the registrant shall immediately deliver his/her
Certificate of Registration, any order forms, and

[[Page 8520]]
any import or export permits in his/her possession to the nearest
office of the Administration. The suspension or revocation of a
registration shall suspend or revoke any individual manufacturing or
procurement quota fixed for the registrant pursuant to part 1303 of
this chapter and any import or export permits issued to the registrant
pursuant to part 1312 of this chapter. Also, upon service of the order
of the Administrator revoking or suspending registration, the
registrant shall, as instructed by the Administrator:
(1) Deliver all controlled substances in his/her possession to the
nearest office of the Administration or to authorized agents of the
Administration; or
(2) Place all controlled substances in his/her possession under
seal as described in sections 304(f) or 1008(d)(6) of the Act (21
U.S.C. 824(f) or 958(d)(6)).
(g) In the event that revocation or suspension is limited to a
particular controlled substance or substances, the registrant shall be
given a new Certificate of Registration for all substances not affected
by such revocation or suspension; no fee shall be required to be paid
for the new Certificate of Registration. The registrant shall deliver
the old Certificate of Registration and, if appropriate, any order
forms in his/her possession to the nearest office of the
Administration. The suspension or revocation of a registration, when
limited to a particular basic class or classes of controlled
substances, shall suspend or revoke any individual manufacturing or
procurement quota fixed for the registrant for such class or classes
pursuant to part 1303 of this chapter and any import or export permits
issued to the registrant for such class or classes pursuant to part
1312 of this chapter. Also, upon service of the order of the
Administrator revoking or suspending registration, the registrant
shall, as instructed by the Administrator:
(1) Deliver to the nearest office of the Administration or to
authorized agents of the Administration all of the particular
controlled substance or substances affected by the revocation or
suspension which are in his/her possession; or
(2) Place all of such substances under seal as described in
sections 304(f) or 958(d)(6) of the Act (21 U.S.C. 824(f) or
958(d)(6)).
(h) Any suspension shall continue in effect until the conclusion of
all proceedings upon the revocation or suspension, including any
judicial review thereof, unless sooner withdrawn by the Administrator
or dissolved by a court of competent jurisdiction. Any registrant whose
registration is suspended under paragraph (e) of this section may
request a hearing on the revocation or suspension of his/her
registration at a time earlier than specified in the order to show
cause pursuant to Sec. 1301.37, which request shall be granted by the
Administrator, who shall fix a date for such hearing as early as
reasonably possible.
(i) In the event that an applicant for reregistration (who is doing
business under a registration previously granted and not revoked or
suspended) has applied for reregistration at least 45 days before the
date on which the existing registration is due to expire, and the
Administrator has issued no order on the application on the date on
which the existing registration is due to expire, the existing
registration of the applicant shall automatically be extended and
continue in effect until the date on which the Administrator so issues
his/her order. The Administrator may extend any other existing
registration under the circumstances contemplated in this section even
though the registrant failed to apply for reregistration at least 45
days before expiration of the existing registration, with or without
request by the registrant, if the Administrator finds that such
extension is not inconsistent with the public health and safety.

Sec. 1301.37 Order to show cause.

(a) If, upon examination of the application for registration from
any applicant and other information gathered by the Administration
regarding the applicant, the Administrator is unable to make the
determinations required by the applicable provisions of section 303
and/or section 1008 of the Act (21 U.S.C. 823 and 958) to register the
applicant, the Administrator shall serve upon the applicant an order to
show cause why the registration should not be denied.
(b) If, upon information gathered by the Administration regarding
any registrant, the Administrator determines that the registration of
such registrant is subject to suspension or revocation pursuant to
section 304 or section 1008 of the Act (21 U.S.C. 824 and 958), the
Administrator shall serve upon the registrant an order to show cause
why the registration should not be revoked or suspended.
(c) The order to show cause shall call upon the applicant or
registrant to appear before the Administrator at a time and place
stated in the order, which shall not be less than 30 days after the
date of receipt of the order. The order to show cause shall also
contain a statement of the legal basis for such hearing and for the
denial, revocation, or suspension of registration and a summary of the
matters of fact and law asserted.
(d) Upon receipt of an order to show cause, the applicant or
registrant must, if he/she desires a hearing, file a request for a
hearing pursuant to Sec. 1301.43. If a hearing is requested, the
Administrator shall hold a hearing at the time and place stated in the
order, pursuant to Sec. 1301.41.
(e) When authorized by the Administrator, any agent of the
Administration may serve the order to show cause.

Hearings

Sec. 1301.41 Hearings generally.

(a) In any case where the Administrator shall hold a hearing on any
registration or application therefor, the procedures for such hearing
shall be governed generally by the adjudication procedures set forth in
the Administrative Procedure Act (5 U.S.C. 551-559) and specifically by
Secs. 303, 304, and 1008 of the Act (21 U.S.C. 823-824 and 958), by
Secs. 1301.42-1301.46 of this part, and by the procedures for
administrative hearings under the Act set forth in Secs. 1316.41-
1316.67 of this chapter.
(b) Any hearing under this part shall be independent of, and not in
lieu of, criminal prosecutions or other proceedings under the Act or
any other law of the United States.

Sec. 1301.42 Purpose of hearing.

If requested by a person entitled to a hearing, the Administrator
shall hold a hearing for the purpose of receiving factual evidence
regarding the issues involved in the denial, revocation, or suspension
of any registration, and the granting of any application for
registration to manufacture in bulk a basic class of controlled
substance listed in Schedule I or II. Extensive argument should not be
offered into evidence but rather presented in opening or closing
statements of counsel or in memoranda or proposed findings of fact and
conclusions of law.

Sec. 1301.43 Request for hearing or appearance; waiver.

(a) Any person entitled to a hearing pursuant to Secs. 1301.32 or
1301.34-1301.36 and desiring a hearing shall, within 30 days after the
date of receipt of the order to show cause (or the date of publication
of notice of the application for registration in the Federal Register
in the case of

[[Page 8521]]
Sec. 1301.34), file with the Administrator a written request for a
hearing in the form prescribed in Sec. 1316.47 of this chapter.
(b) Any person entitled to participate in a hearing pursuant to
Sec. 1301.34 or Sec. 1301.35(b) and desiring to do so shall, within 30
days of the date of publication of notice of the request for a hearing
in the Federal Register, file with the Administrator a written notice
of intent to participate in such hearing in the form prescribed in
Sec. 1316.48 of this chapter. Any person filing a request for a hearing
need not also file a notice of appearance.
(c) Any person entitled to a hearing or to participate in a hearing
pursuant to Sec. 1301.32 or Secs. 1301.34-1301.36 may, within the
period permitted for filing a request for a hearing or a notice of
appearance, file with the Administrator a waiver of an opportunity for
a hearing or to participate in a hearing, together with a written
statement regarding such person's position on the matters of fact and
law involved in such hearing. Such statement, if admissible, shall be
made a part of the record and shall be considered in light of the lack
of opportunity for cross-examination in determining the weight to be
attached to matters of fact asserted therein.
(d) If any person entitled to a hearing or to participate in a
hearing pursuant to Secs. 1301.32 or 1301.34-1301.36 fails to file a
request for a hearing or a notice of appearance, or if such person so
files and fails to appear at the hearing, such person shall be deemed
to have waived the opportunity for a hearing or to participate in the
hearing, unless such person shows good cause for such failure.
(e) If all persons entitled to a hearing or to participate in a
hearing waive or are deemed to waive their opportunity for the hearing
or to participate in the hearing, the Administrator may cancel the
hearing, if scheduled, and issue his/her final order pursuant to
Sec. 1301.46 without a hearing.

Sec. 1301.44 Burden of proof.

(a) At any hearing on an application to manufacture any controlled
substance listed in Schedule I or II, the applicant shall have the
burden of proving that the requirements for such registration pursuant
to section 303(a) of the Act (21 U.S.C. 823(a)) are satisfied. Any
other person participating in the hearing pursuant to Sec. 1301.35(b)
shall have the burden of proving any propositions of fact or law
asserted by such person in the hearing.
(b) At any hearing on the granting or denial of an applicant to be
registered to conduct a narcotic treatment program or as a compounder,
the applicant shall have the burden of proving that the requirements
for each registration pursuant to section 303(g) of the Act (21 U.S.C.
823(g)) are satisfied.
(c) At any hearing on the granting or denial of an application to
be registered to import or export any controlled substance listed in
Schedule I or II, the applicant shall have the burden of proving that
the requirements for such registration pursuant to sections 1008 (a)
and (d) of the Act (21 U.S.C. 958 (a) and (d)) are satisfied. Any other
person participating in the hearing pursuant to Sec. 1301.34 shall have
the burden of proving any propositions of fact or law asserted by him/
her in the hearings.
(d) At any other hearing for the denial of a registration, the
Administration shall have the burden of proving that the requirements
for such registration pursuant to section 303 or section 1008 (c) and
(d) of the Act (21 U.S.C. 823 or 958 (c) and (d)) are not satisfied.
(e) At any hearing for the revocation or suspension of a
registration, the Administration shall have the burden of proving that
the requirements for such revocation or suspension pursuant to section
304(a) or section 1008(d) of the Act (21 U.S.C. 824(a) or 958(d)) are
satisfied.

Sec. 1301.45 Time and place of hearing.

The hearing will commence at the place and time designated in the
order to show cause or notice of hearing published in the Federal
Register (unless expedited pursuant to Sec. 1301.36(h)) but thereafter
it may be moved to a different place and may be continued from day to
day or recessed to a later day without notice other than announcement
thereof by the presiding officer at the hearing.

Sec. 1301.46 Final order.

As soon as practicable after the presiding officer has certified
the record to the Administrator, the Administrator shall issue his/her
order on the granting, denial, revocation, or suspension of
registration. In the event that an application for registration to
manufacture in bulk a basic class of any controlled substance listed in
Schedule I or II is granted, or any application for registration is
denied, or any registration is revoked or suspended, the order shall
include the findings of fact and conclusions of law upon which the
order is based. The order shall specify the date on which it shall take
effect. The Administrator shall serve one copy of his/her order upon
each party in the hearing.

Modification, Transfer and Termination of Registration

Sec. 1301.51 Modification in registration.

Any registrant may apply to modify his/her registration to
authorize the handling of additional controlled substances or to change
his/her name or address, by submitting a letter of request to the
Registration Unit, Drug Enforcement Administration, Department of
Justice, Post Office Box 28083, Central Station, Washington, DC 20005.
The letter shall contain the registrant's name, address, and
registration number as printed on the certificate of registration, and
the substances and/or schedules to be added to his/her registration or
the new name or address and shall be signed in accordance with
Sec. 1301.13(j). If the registrant is seeking to handle additional
controlled substances listed in Schedule I for the purpose of research
or instructional activities, he/she shall attach three copies of a
research protocol describing each research project involving the
additional substances, or two copies of a statement describing the
nature, extent, and duration of such instructional activities, as
appropriate. No fee shall be required to be paid for the modification.
The request for modification shall be handled in the same manner as an
application for registration. If the modification in registration is
approved, the Administrator shall issue a new certificate of
registration (DEA Form 223) to the registrant, who shall maintain it
with the old certificate of registration until expiration.

Sec. 1301.52 Termination of registration; transfer of registration;
distribution upon discontinuance of business.

(a) Except as provided in paragraph (b) of this section, the
registration of any person shall terminate if and when such person
dies, ceases legal existence, or discontinues business or professional
practice. Any registrant who ceases legal existence or discontinues
business or professional practice shall notify the Administrator
promptly of such fact.
(b) No registration or any authority conferred thereby shall be
assigned or otherwise transferred except upon such conditions as the
Administration may specifically designate and then only pursuant to
written consent. Any person seeking authority to transfer a
registration shall submit a written request, providing full details
regarding the proposed transfer of registration, to the Deputy
Assistant Administrator, Office of Diversion Control, Drug Enforcement
Administration,

[[Page 8522]]
Department of Justice, Washington, DC 20537.
(c) Any registrant desiring to discontinue business activities
altogether or with respect to controlled substances (without
transferring such business activities to another person) shall return
for cancellation his/her certificate of registration, and any
unexecuted order forms in his/her possession, to the Registration Unit,
Drug Enforcement Administration, Department of Justice, Post Office Box
28083, Central Station, Washington, DC 20005. Any controlled substances
in his/her possession may be disposed of in accordance with
Sec. 1307.21 of this chapter.
(d) Any registrant desiring to discontinue business activities
altogether or with respect to controlled substance (by transferring
such business activities to another person) shall submit in person or
by registered or certified mail, return receipt requested, to the
Special Agent in Charge in his/her area, at least 14 days in advance of
the date of the proposed transfer (unless the Special Agent in Charge
waives this time limitation in individual instances), the following
information:
(1) The name, address, registration number, and authorized business
activity of the registrant discontinuing the business (registrant-
transferor);
(2) The name, address, registration number, and authorized business
activity of the person acquiring the business (registrant-transferee);
(3) Whether the business activities will be continued at the
location registered by the person discontinuing business, or moved to
another location (if the latter, the address of the new location should
be listed);
(4) Whether the registrant-transferor has a quota to manufacture or
procure any controlled substance listed in Schedule I or II (if so, the
basic class or class of the substance should be indicated); and
(5) The date on which the transfer of controlled substances will
occur.
(e) Unless the registrant-transferor is informed by the Special
Agent in Charge, before the date on which the transfer was stated to
occur, that the transfer may not occur, the registrant-transferor may
distribute (without being registered to distribute) controlled
substances in his/her possession to the registrant-transferee in
accordance with the following:
(1) On the date of transfer of the controlled substances, a
complete inventory of all controlled substances being transferred shall
be taken in accordance with Sec. 1304.11 of this chapter. This
inventory shall serve as the final inventory of the registrant-
transferor and the initial inventory of the registrant-transferee, and
a copy of the inventory shall be included in the records of each
person. It shall not be necessary to file a copy of the inventory with
the Administration unless requested by the Special Agent in Charge.
Transfers of any substances listed in Schedule I or II shall require
the use of order forms in accordance with part 1305 of this chapter.
(2) On the date of transfer of the controlled substances, all
records required to be kept by the registrant-transferor with reference
to the controlled substances being transferred, under part 1304 of this
chapter, shall be transferred to the registrant-transferee.
Responsibility for the accuracy of records prior to the date of
transfer remains with the transferor, but responsibility for custody
and maintenance shall be upon the transferee.
(3) In the case of registrants required to make reports pursuant to
part 1304 of this chapter, a report marked ``Final'' will be prepared
and submitted by the registrant-transferor showing the disposition of
all the controlled substances for which a report is required; no
additional report will be required from him, if no further transactions
involving controlled substances are consummated by him. The initial
report of the registrant-transferee shall account for transactions
beginning with the day next succeeding the date of discontinuance or
transfer of business by the transferor-registrant and the substances
transferred to him shall be reported as receipts in his/her initial
report.

Sec. 1301.75 Physical security controls for practitioners.

* * * * *
(b) Controlled substances listed in Schedules II, III, IV, and V
shall be stored in a securely locked, substantially constructed
cabinet. However, pharmacies and institutional practitioners may
disperse such substances throughout the stock of noncontrolled
substances in such a manner as to obstruct the theft or diversion of
the controlled substances.
* * * * *
6. Section 1301.76 is proposed to be amended by revising paragraph
(c) to read as follows:

Sec. 1301.76 Other security controls for practitioners.

* * * * *
(c) Whenever the registrant distributes a controlled substance
(without being registered as a distributor, as permitted in
Sec. 1301.13(e)(1) and/or Secs. 1307.11-1307.12) he/she shall comply
with the requirements imposed on nonpractitioners in Sec. 1301.74 (a),
(b), and (e).

Sec. 1301.72 [Amended]

7. In 21 CFR 1301.72(b)(4)(i)(b) remove the word ``lay'' and add,
in its place, the word ``lag''.

PART 1302--[AMENDED]

1. The authority citation for part 1302 continues to read as
follows:

Authority: 21 U.S.C. 821, 825, 871(b), 958 (e).
2. Section 1302.02 is proposed to be revised to read as follows:

Sec. 1302.02 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or Part 1300 of this chapter.
3. Section 1302.04 is proposed to be revised to read as follows:

Sec. 1302.04 Location and size of symbol on label and labeling.

The symbol shall be prominently located on the label or the
labeling of the commercial container and/or the panel of the commercial
container normally displayed to dispensers of any controlled substance.
The symbol on labels shall be clear and large enough to afford easy
identification of the schedule of the controlled substance upon
inspection without removal from the dispenser's shelf. The symbol on
all other labeling shall be clear and large enough to afford prompt
identification of the controlled substance upon inspection of the
labeling.

Sec. 1302.05 [Removed]

4. Section 1302.05 is proposed to be removed.
5. Section 1302.06 is proposed to be redesignated as Section
1302.05 and revised to read as follows:

Sec. 1302.05 Effective dates of labeling requirements.

All labels on commercial containers of, and all labeling of, a
controlled substance which either is transferred to another schedule or
is added to any schedule shall comply with the requirements of
Sec. 1302.03, on or before the effective date established in the final
order for the transfer or addition.
6. Section 1302.07 is proposed to be redesignated as Sec. 1302.06
and revised to read as follows:

Sec. 1302.06 Sealing of controlled substances.

On each bottle, multiple dose vial, or other commercial container
of any

[[Page 8523]]
controlled substance, there shall be securely affixed to the stopper,
cap, lid, covering, or wrapper or such container a seal to disclose
upon inspection any tampering or opening of the container.
7. Section 1302.08 is proposed to be redesignated as Sec. 1302.07,
and revised to read as follows:

Sec. 1302.07 Labeling and packaging requirements for imported and
exported substances.

(a) The symbol requirements of Secs. 1302.03-1302.05 apply to every
commercial container containing, and to all labeling of, controlled
substances imported into the jurisdiction of and/or the customs
territory of the United States.
(b) The symbol requirements of Secs. 1302.03-1302.05 do not apply
to any commercial containers containing, or any labeling of, a
controlled substance intended for export from the jurisdiction of the
United States.
(c) The sealing requirements of Sec. 1302.06 apply to every bottle,
multiple dose vial, or other commercial container of any controlled
substance listed in schedule I or II, or any narcotic controlled
substance listed in schedule III or IV, imported into, exported from,
or intended for export from, the jurisdiction of and/or the customs
territory of the United States.

PART 1303--[AMENDED]

1. The authority citation for part 1303 continues to read as
follows:

Authority: 21 U.S.C. 821, 826, 871(b).

2. Section 1303.02 is proposed to be revised to read as follows:

Sec. 1303.02 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.
3. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

PART 1304--[AMENDED]

1. The authority citation for part 1304 is proposed to be corrected
to read as follows:

Authority: 21 U.S.C. 821, 827, 871(b), 958(e), 965, unless
otherwise noted.

2. Section 1304.02 is proposed to be revised to read as follows:

Sec. 1304.02 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.
3. Section 1304.03 is proposed to be amended by removing paragraphs
(g) and (h), and revising paragraph (f) to read as follows:

Sec. 1304.03 Persons required to keep records and file reports.

* * * * *
(f) Registered persons using any controlled substances while
conducting preclinical research, in teaching at a registered
establishment which maintains records with respect to such substances
or conducting research in conformity with an exemption granted under
section 505(i) or 512(j) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355(i) or 360b(j)) at a registered establishment which
maintains records in accordance with either of those sections are not
required to keep records if he/she notifies the Administration of the
name, address, and registration number of the establishment maintaining
such records. This notification shall be given at the time the person
applies for registration or reregistration and shall be made in the
form of an attachment to the application, which shall be filed with the
application.
4. Section 1304.04 is proposed to be amended by removing
``executed'' in paragraph (a) and by adding ``executed'' and by
revising paragraphs (e) and (h) to read as follows:

Sec. 1304.04 Maintenance of records and inventories.

* * * * *
(e) All central recordkeeping permits previously issued by the
Administration expired September 30, 1980.
* * * * *
(h) Each registered pharmacy shall maintain the inventories and
records of controlled substances as follows:
(1) Inventories and records of all controlled substances listed in
Schedules I and II shall be maintained separately from all other
records of the pharmacy, and prescriptions for such substances shall be
maintained in a separate prescription file; and
(2) Inventories and records of controlled substances listed in
Schedules III, IV, and V shall be maintained either separately from all
other records of the pharmacy or in such form that the information
required is readily retrievable from ordinary business records of the
pharmacy, and prescriptions for such substances shall be maintained
either in a separate prescription file for controlled substances listed
in Schedules III, IV, and V only or in such form that they are readily
retrievable from the other prescription records of the pharmacy.
Prescriptions will be deemed readily retrievable if, at the time they
are initially filed, the face of the prescription is stamped in red ink
in the lower right corner with the letter ``C'' no less than 1-inch
high and filed either in the prescription file for controlled
substances listed in Schedules I and II or in the usual consecutively
numbered prescription file for non-controlled substances. However, if a
pharmacy employs an ADP system or other electronic recordkeeping system
for prescriptions which permits

[[Page 8524]]
identification by prescription number and retrieval of original
documents by prescriber's name, patient's name, drug dispensed, and
date filled, then the requirement to mark the hard copy prescription
with a red ``C'' is waived.
5. Section 1304.11 is proposed to be revised to read as follows:

Sec. 1304.11 Inventory requirements.

(a) General requirements. Each inventory shall contain a complete
and accurate record of all controlled substances on hand on the date
the inventory is taken, and shall be maintained in written,
typewritten, or printed form at the registered location. An inventory
taken by use of an oral recording device must be promptly transcribed.
Controlled substances shall be deemed to be ``on hand'' if they are in
the possession of or under the control of the registrant, including
substances returned by a customer, ordered by a customer but not yet
invoiced, stored in a warehouse on behalf of the registrant, and
substances in the possession of employees of the registrant and
intended for distribution as complimentary samples. A separate
inventory shall be made for each registered location and each
independent activity registered, except as provided in paragraph (e)(4)
of this section. In the event controlled substances in the possession
or under the control of the registrant are stored at a location for
which he/she is not registered, the substances shall be included in the
inventory of the registered location to which they are subject to
control or to which the person possessing the substance is responsible.
The inventory may be taken either as of opening of business or as of
the close of business on the inventory date and it shall be indicated
on the inventory.
(b) Initial inventory date. Every person required to keep records,
shall take an inventory of all stocks of controlled substances on hand
on the date he/she first engages in the manufacture, distribution, or
dispensing of controlled substances, in accordance with paragraph (e)
of this section as applicable. In the event a person commences business
with no controlled substances on hand, he/she shall record this fact as
the initial inventory.
(c) Biennial inventory date. After the initial inventory is taken,
the registrant shall take a new inventory of all stocks of controlled
substances on hand at least every two years. The biennial inventory may
be taken on the day of the year on which the initial inventory was
taken or on any other fixed date which does not vary by more than 6
months from the biennial date that would otherwise apply. If the
registrant elects to take the biennial inventory on another fixed date,
he/she shall notify the Administration of this election and of the date
on which the biennial inventory will be taken.
(d) Inventory date for newly controlled substances. On the
effective date of a rule by the Administrator pursuant to
Secs. 1308.45, 1308.46, or Sec. 1308.47 of this chapter adding a
substance to any schedule of controlled substances, which substance
was, immediately prior to that date, not listed on any such schedule,
every registrant required to keep records who possesses that substance
shall take an inventory of all stocks of the substance on hand.
Thereafter, such substance shall be included in each inventory made by
the registrant pursuant to paragraph (c) of this section.
(e) Inventories of manufacturers, distributors, dispensers,
researchers, importers, exporters and chemical analysts. Each person
registered or authorized (by Secs. 1301.13 or Secs. 1307.11-1307.13 of
this chapter) to manufacture, distribute, dispense, import, export,
conduct research or chemical analysis with controlled substances and
required to keep records pursuant to Sec. 1304.03 shall include in the
inventory the information listed below.
(1) Inventories of manufacturers. Each person registered or
authorized to manufacture controlled substances shall include the
following information in the inventory:
(i) For each controlled substance in bulk form to be used in (or
capable of use in) the manufacture of the same or other controlled or
non-controlled substances in finished form, the inventory shall
include:
(A) the name of the substance and
(B) the total quantity of the substance to the nearest metric unit
weight consistent with unit size.
(ii) For each controlled substance in the process of manufacture on
the inventory date, the inventory shall include:
(A) The name of the substance;
(B) the quantity of the substance in each batch and/or stage of
manufacture, identified by the batch number or other appropriate
identifying number;
(C) the physical form which the substance is to take upon
completion of the manufacturing process (e.g., granulations, tablets,
capsules, or solutions), identified by the batch number or other
appropriate identifying number, and if possible the finished form of
the substance (e.g., 10-milligram tablet or 10-milligram concentration
per fluid ounce or milliliter) and the number or volume thereof.
(iii) For each controlled substance in finished form the inventory
shall include:
(A) The name of the substance;
(B) each finished form of the substance (e.g., 10-milligram tablet
or 10-milligram concentration per fluid ounce or milliliter);
(C) the number of units or volume of each finished form in each
commercial container (e.g., 100-tablet bottle or 3-milliliter vial);
and
(D) the number of commercial containers of each such finished form
(e.g. four 100-tablet bottles or six 3-milliliter vials).
(iv) For each controlled substance not included in paragraphs
(e)(1) (i), (ii) or (iii) of this section (e.g., damaged, defective or
impure substances awaiting disposal, substances held for quality
control purposes, or substances maintained for extemporaneous
compoundings) the inventories shall include:
(A) The name of the substance;
(B) the total quantity of the substance to the nearest metric unit
weight or the total number of units of finished form; and
(C) the reason for the substance being maintained by the registrant
and whether such substance is capable of use in the manufacture of any
controlled substance in finished form.
(2) Inventories of distributors. Each person registered or
authorized to distribute controlled substances shall include in the
inventory the same information required of manufacturers pursuant to
paragraphs (e)(1) (iii) and (iv) of this section.
(3) Inventories of dispensers and researchers. Each person
registered or authorized to dispense or conduct research with
controlled substances shall include in the inventory the same
information required of manufacturers pursuant to paragraphs (e)(1)
(iii) and (iv) of this section. In determining the number of units of
each finished form of a controlled substance in a commercial container
which has been opened, the dispenser shall do as follows:
(i) If the substance is listed in Schedule I or II, make an exact
count or measure of the contents or
(ii) if the substance is listed in Schedule III, IV or V, make an
estimated count or measure of the contents, unless the container holds
more than 1,000 tablets or capsules in which case he/she must make an
exact count of the contents.
(4) Inventories of importers and exporters. Each person registered
or

[[Page 8525]]
authorized to import or export controlled substances shall include in
the inventory, the same information required of manufacturers pursuant
to paragraphs (e)(1) (iii) and (iv) of this section. Each such person
who is also registered as a manufacturer or as a distributor shall
include in his/her inventory as an importer or exporter only those
stocks of controlled substances that are actually separated from his
stocks as a manufacturer or as a distributor (e.g., in transit or in
storage for shipment).
(5) Inventories of chemical analysts. Each person registered or
authorized to conduct chemical analysis with controlled substances
shall include in his inventory the same information required of
manufacturers pursuant to paragraphs (e)(1) (iii) and (iv) of this
section as to substances which have been manufactured, imported, or
received by such person. If less than 1 kilogram of any controlled
substance (other than a hallucinogenic controlled substance listed in
Schedule I), or less than 20 grams of a hallucinogenic substance listed
in Schedule I (other than lysergic acid diethylamide), or less than 0.5
gram of lysergic acid diethylamide, is on hand at the time of
inventory, that substance need not be included in the inventory.
Laboratories of the Administration may possess up to 150 grams of any
hallucinogenic substance in Schedule I without regard to a need for an
inventory of those substances. No inventory is required of known or
suspected controlled substances received as evidentiary materials for
analysis.

Secs. 1304.12--1304.19 [Removed]

6. Sections 1304.12, 1304.13, 1304.14, 1304.15, 1304.16, 1304.17,
1304.18 and 1304.19 are proposed to be removed.
7. Section 1304.21 is proposed to be amended by revising paragraphs
(a) and (c) to read as follows:

Sec. 1304.21 General requirements for continuing records.

(a) Every registrant required to keep records pursuant to Section
1304.03 shall maintain on a current basis a complete and accurate
record of each such substance manufactured, imported, received, sold,
delivered, exported, or otherwise disposed of by him/her, except that
no registrant shall be required to maintain a perpetual inventory.
(b) * * *
(c) Separate records shall be maintained by a registrant for each
independent activity for which he/she is registered, except as provided
in Sec. 1304.22(d).
* * * * *
8. Section 1304.22 is proposed to be revised to read as follows:

1304.22 Records for manufacturers, distributors, dispensers,
researchers, importers and exporters.

Each person registered or authorized (by Sec. 1301.13(e) or
Secs. 1307.11-1307.13 of this chapter) to manufacture, distribute,
dispense, import, export or conduct research with controlled substances
shall maintain records with the information listed below.
(a) Records for manufacturers. Each person registered or authorized
to manufacture controlled substances shall maintain records with the
following information:
(1) For each controlled substance in bulk form to be used in, or
capable of use in, or being used in, the manufacture of the same or
other controlled or noncontrolled substances in finished form,
(i) The name of the substance;
(ii) The quantity manufactured in bulk form by the registrant,
including the date, quantity and batch or other identifying number of
each batch manufactured;
(iii) The quantity received from other persons, including the date
and quantity of each receipt and the name, address, and registration
number of the other person from whom the substance was received;
(iv) The quantity imported directly by the registrant (under a
registration as an importer) for use in manufacture by him/her,
including the date, quantity, and import permit or declaration number
for each importation;
(v) The quantity used to manufacture the same substance in finished
form, including:
(A) The date and batch or other identifying number of each
manufacture;
(B) The quantity used in the manufacture;
(C) The finished form (e.g., 10-milligram tablets or 10-milligram
concentration per fluid ounce or milliliter);
(D) The number of units of finished form manufactured;
(E) The quantity used in quality control;
(F) The quantity lost during manufacturing and the causes
therefore, if known;
(G) The total quantity of the substance contained in the finished
form;
(H) The theoretical and actual yields; and
(I) Such other information as is necessary to account for all
controlled substances used in the manufacturing process;
(vi) The quantity used to manufacture other controlled and
noncontrolled substances, including the name of each substance
manufactured and the information required in paragraph (a)(1)(v) of
this section;
(vii) The quantity distributed in bulk form to other persons,
including the date and quantity of each distribution and the name,
address, and registration number of each person to whom a distribution
was made;
(viii) The quantity exported directly by the registrant (under a
registration as an exporter), including the date, quantity, and export
permit or declaration number of each exportation;
(ix) The quantity distributed or disposed of in any other manner by
the registrant (e.g., by distribution of complimentary samples or by
destruction), including the date and manner of distribution or
disposal, the name, address, and registration number of the person to
whom distributed, and the quantity distributed or disposed;
(x) The originals of all written certifications of available
procurement quotas submitted by other persons (as required by
Sec. 1303.12(f) of this chapter) relating to each order requiring the
distribution of a basic class of controlled substance listed in
Schedule I or II.
(2) For each controlled substance in finished form,
(i) The name of the substance;
(ii) Each finished form (e.g., 10-milligram tablet or 10-milligram
concentration per fluid ounce or milliliter) and the number of units or
volume of finished form in each commercial container (e.g., 100-tablet
bottle or 3-milliliter vial);
(iii) The number of containers of each such commercial finished
form manufactured from bulk form by the registrant, including the
information required pursuant to paragraph (a)(1)(v) of this section;
(iv) The number of units of finished forms and/or commercial
containers received from other persons, including the date of and
number of units and/or commercial containers in each receipt and the
name, address, and registration number of the person from whom the
units were received;
(v) The number of units of finished forms and/or commercial
containers imported directly by the person (under a registration or
authorization to import), including the date of, the number of units
and/or commercial containers in, and the import permit or declaration
number for, each importation.

[[Page 8526]]

(vi) The number of units and/or commercial containers manufactured
by the registrant from units in finished form received from others or
imported, including:
(A) The date and batch or other identifying number of each
manufacture;
(B) The operation performed (e.g., repackaging or relabeling);
(C) The number of units of finished form used in the manufacture,
the number manufactured and the number lost during manufacture, with
the causes for such losses, if known; and
(D) Such other information as is necessary to account for all
controlled substances used in the manufacturing process;
(vii) The number of commercial containers distributed to other
persons, including the date of and number of containers in each
distribution, and the name, address, and registration number of the
person to whom the containers were distributed;
(viii) The number of commercial containers exported directly by the
registrant (under a registration as an exporter), including the date,
number of containers and export permit or declaration number for each
exportation; and
(ix) The number of units of finished forms and/or commercial
containers distributed or disposed of in any other manner by the
registrant (e.g., by distribution of complimentary samples or by
destruction), including the date and manner of distribution or
disposal, the name address, and registration number of the person to
whom distributed, and the quantity in finished form distributed or
disposed.
(b) Records for distributors. Each person registered or authorized
to distribute controlled substances shall maintain records with the
same information required of manufacturers pursuant to paragraphs
(a)(2) (i), (ii), (iv), (v), (vii), (viii) and (ix) of this section.
(c) Records for dispensers and researchers. Each person registered
or authorized to dispense or conduct research with controlled
substances shall maintain records with the same information required of
manufacturers pursuant to paragraph (a)(2) (i), (ii), (iv) and (ix) of
this section. In addition, records shall be maintained of the number of
units or volume of such finished form dispensed, including the name and
address of the person to whom it was dispensed, the date of dispensing,
the number of units or volume dispensed, and the written or typewritten
name or initials of the individual who dispensed or administered the
substance on behalf of the dispenser.
(d) Records for importers and exporters. Each person registered or
authorized to import or export controlled substances shall maintain
records with the same information required of manufacturers pursuant to
paragraphs (a)(2) (i), (iv), (v) and (vii) of this section. In
addition, the quantity disposed of in any other manner by the
registrant (except quantities used in manufacturing by an importer
under a registration as a manufacturer), which quantities are to be
recorded pursuant to paragraphs (a)(1) (iv) and (v) of this section;
and the quantity (or number of units or volume in finished form)
exported, including the date, quantity (or number of units or volume),
and the export permit or declaration number for each exportation, but
excluding all quantities (and number of units and volumes) manufactured
by an exporter under a registration as a manufacturer, which quantities
(and numbers of units and volumes) are to be recorded pursuant to
paragraphs (a)(1)(xiii) or (a)(2)(xiii) of this section.

Secs. 1304.23--1304.26 [Removed]

9. Sections 1304.23 through 1304.26 are proposed to be removed.

Sec. 1304.27 [Redesignated as Sec. 1304.23]

10. Section 1304.27 is proposed to be redesignated as Sec. 1304.23.

Sec. 1304.28 [Redesignated as Sec. 1304.24 and amended]

11. Section 1304.28 is proposed to be redesignated as Sec. 1304.24
and reference in Sec. 1304.28(b) to ``Sec. 1304.24'' is proposed to be
revised to read ``Sec. 1304.22'', and in paragraph (d), the words
``part 1401 of this title'' are proposed to be revised to read ``42 CFR
Part 2.''

Sec. 1304.29 [Redesignated as Sec. 1304.25]

12. Section 1304.29 is proposed to be redesignated as Sec. 1304.25.
13. Section 1304.31 is proposed to be revised to read as follows:

Sec. 1304.31 Reports from manufacturers importing narcotic raw
material.

(a) Every manufacturer which imports or manufactures from narcotic
raw material (opium, poppy straw, and concentrate of poppy straw),
shall submit information which accounts for the importation and for all
manufacturing operations performed between importation and the
production in bulk or finished marketable products, standardized in
accordance with the U.S. Pharmacopeia, National Formulary or other
recognized medical standards. Reports shall be signed by the authorized
official and submitted quarterly on company letterhead to the Drug
Enforcement Administration, Drug and Chemical Evaluation Section,
Washington, D.C. 20537, on or before the 15th day of the month
immediately following the period for which it is submitted.
(b) The following information shall be submitted for each type of
narcotic raw material (quantities are expressed as grams of anhydrous
morphine alkaloid):
(1) Beginning inventory;
(2) Gains on reweighing;
(3) Imports;
(4) Other receipts;
(5) Quantity put into process;
(6) Losses on reweighing;
(7) Other dispositions and
(8) Ending inventory.
(c) The following information shall be submitted for each narcotic
raw material derivative including morphine, codeine, thebaine,
oxycodone, hydrocodone, medicinal opium, manufacturing opium, crude
alkaloids and other derivatives (quantities are expressed as grams of
anhydrous base or anhydrous morphine alkaloid for manufacturing opium
and medicinal opium):
(1) Beginning inventory;
(2) Gains on reweighing;
(3) Quantity extracted from narcotic raw material;
(4) Quantity produced/manufactured/synthesized;
(5) Quantity sold;
(6) Quantity returned to conversion processes for reworking;
(7) Quantity used for conversion;
(8) Quantity placed in process;
(9) Other dispositions;
(10) Losses on reweighing and
(11) Ending inventory.
(d) The following information shall be submitted for importation of
each narcotic raw material:
(1) Import permit number;
(2) Date shipment arrived at the United States port of entry;
(3) Actual quantity shipped;
(4) Assay (percent) of morphine, codeine and thebaine and
(5) Quantity shipped, expressed as anhydrous morphine alkaloid.
(e) Upon importation of crude opium, samples will be selected and
assays made by the importing manufacturer in the manner and according
to the method specified in the U.S. Pharmacopoeia. Where final assay
data is not determined at the time of rendering report, the report
shall be made on the basis of the best data available, subject to
adjustment, and the necessary adjusting entries shall be made on the
next report.
(f) Where factory procedure is such that partial withdrawals of
opium are

[[Page 8527]]
made from individual containers, there shall be attached to each
container a stock record card on which shall be kept a complete record
of all withdrawals therefrom.
(g) All in-process inventories should be expressed in terms of end-
products and not precursors. Once precursor material has been changed
or placed into process for the manufacture of a specified end-product,
it must no longer be accounted for as precursor stocks available for
conversion or use, but rather as end-product in-process inventories.
14. Section 1304.32 is proposed to be revised to read as follows:

Sec. 1304.32 Reports of manufacturers importing coca leaves.

(a) Every manufacturer importing or manufacturing from raw coca
leaves shall submit information accounting for the importation and for
all manufacturing operations performed between the importation and the
manufacture of bulk or finished products standardized in accordance
with U.S. Pharmacopoeia, National Formulary, or other recognized
standards. The reports shall be submitted quarterly on company
letterhead to the Drug Enforcement Administration, Drug and Chemical
Evaluation Section, Washington, DC 20537, on or before the 15th day of
the month immediately following the period for which it is submitted.
(b) The following information shall be submitted for raw coca leaf,
ecgonine, ecgonine for conversion or further manufacture,
benzoylecgonine, manufacturing coca extracts (list for tinctures and
extracts; and others separately), other crude alkaloids and other
derivatives (quantities should be reported as grams of actual quantity
involved and the cocaine alkaloid content or equivalency):
(1) Beginning inventory;
(2) Imports;
(3) Gains on reweighing;
(4) Quantity purchased;
(5) Quantity produced;
(6) Other receipts;
(7) Quantity returned to processes for reworking;
(8) Material used in purification for sale;
(9) Material used for manufacture or production;
(10) Losses on reweighing;
(11) Material used for conversion;
(12) Other dispositions and
(13) Ending inventory.
(c) The following information shall be submitted for importation of
coca leaves:
(1) Import permit number;
(2) Date the shipment arrived at the United States port of entry;
(3) Actual quantity shipped;
(4) Assay (percent) of cocaine alkaloid and
(5) Total cocaine alkaloid content.
(d) Upon importation of coca leaves, samples will be selected and
assays made by the importing manufacturer in accordance with recognized
chemical procedures. These assays shall form the basis of accounting
for such coca leaves, which shall be accounted for in terms of their
cocaine alkaloid content or equivalency or their total anhydrous coca
alkaloid content. Where final assay data is not determined at the time
of submission, the report shall be made on the basis of the best data
available, subject to adjustment, and the necessary adjusting entries
shall be made on the next report.
(e) Where factory procedure is such that partial withdrawals of
medicinal coca leaves are made from individual containers, there shall
be attached to the container a stock record card on which shall be kept
a complete record of withdrawals therefrom.
(f) All in-process inventories should be expressed in terms of end-
products and not precursors. Once precursor material has been changed
or placed into process for the manufacture of a specified end-product,
it must no longer be accounted for as precursor stocks available for
conversion or use, but rather as end-product in-process inventories.

Sec. 1304.33 [Removed]

15. Section 1304.33 is proposed to be removed.

Sec. 1304.34 [Redesignated as Sec. 1304.33]

16. Section 1304.34 is proposed to be redesignated as Sec. 1304.33
and revised to read as follows:

Sec. 1304.33 Reports to ARCOS.

(a) Reports generally. All reports required by this section shall
be filed with the ARCOS Unit, PO/ 28293, Central Station, Washington,
DC 20005 on DEA Form 333, or on media which contains the data required
by DEA Form 333 and which is acceptable to the ARCOS Unit.
(b) Frequency of reports. Acquisition/Distribution transaction
reports shall be filed every quarter not later than the 15th day of the
month succeeding the quarter for which it is submitted; except that a
registrant may be given permission to file more frequently, (but not
more frequently than monthly), depending on the number of transactions
being reported each time by that registrant. Inventories shall provide
data on the stocks of each reported controlled substance on hand as of
the close of business on December 31 of each year. These reports shall
be filed not later than January 15 of the following year. Manufacturing
transaction reports shall be filed annually for each calendar year not
later than January 15 of the following year.
(c) Persons reporting. For controlled substances in Schedules I, II
or narcotic controlled substances in Schedule III, each person who is
registered to manufacture in bulk or dosage form, or package,
repackage, label or relabel and each person who is registered to
distribute shall report acquisition/distribution transactions. In
addition to reporting acquisition/distribution transactions, each
person who is registered to manufacture controlled substances in bulk
or dosage form shall report manufacturing transactions on controlled
substances in Schedules I and II, each narcotic controlled substance
listed in Schedules III, IV, and V, and on each psychotropic controlled
substance listed in Schedules III and IV as identified in paragraph (d)
of this section.
(d) Substances covered. Manufacturing and acquisition/distribution
transaction reports shall include data on each controlled substance
listed in Schedules I and II and on each narcotic controlled substance
listed in Schedule III (but not on any material, compound, mixture or
preparation containing a quantity of a substance having a stimulant
effect on the central nervous system, which material, compound, mixture
or preparation is listed in Schedule III or on any narcotic controlled
substance listed in Schedule V). Additionally, reports on manufacturing
transactions shall include the following psychotropic controlled
substances listed in Schedules III and IV:

Schedule III

(1) Benzphetamine;
(2) Cyclobarbital;
(3) Methyprylon; and
(4) Phendimetrazine.

Schedule IV

(1) Barbital;
(2) Diethylpropion (Amfepramone);
(3) Ethchlorvynol;
(4) Ethinamate;
(5) Lefetamine (SPA);
(6) Mazindol;
(7) Meprobamate;
(8) Methylphenobarbital;
(9) Phenobarbital;
(10) Phentermine; and
(11) Pipradrol.

Data shall be presented in such a manner as to identify the particular

[[Page 8528]]
form, strength, and trade name, if any, of the product containing the
controlled substance for which the report is being made. For this
purpose, persons filing reports shall utilize the National Drug Code
Number assigned to the product under the National Drug Code System of
the Food and Drug Administration.
(e) Transactions reported. Acquisition/distribution transaction
reports shall provide data on each acquisition to inventory
(identifying whether it is, e.g., by purchase or transfer, return from
a customer, or supply by the Federal Government) and each reduction
from inventory (identifying whether it is, e.g., by sale or transfer,
theft, destruction or seizure by Government agencies). Manufacturing
reports shall provide data on material manufactured, manufacture from
other material, use in manufacturing other material and use in
producing dosage forms.
(f) Exceptions. A registered institutional practitioner who
repackages or relabels exclusively for distribution or who distributes
exclusively to (for dispensing by) agents, employees, or affiliated
institutional practitioners of the registrant may be exempted from
filing reports under this section by applying to the ARCOS Unit of the
Administration.

(Approved by the Office of Management and Budget under control
number 1117-0003)

Secs. 1304.35--1304.38 [Removed]

17. Sections 1304.35 through 1304.38 are proposed to be removed.

PART 1305--[AMENDED]

1. The authority citation for part 1305 continues to read as
follows:

Authority: 21 U.S.C. 821, 828, 871(b) unless otherwise noted.

2. Section 1305.02 is proposed to be revised to read as follows:

Sec. 1305.02 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or Part 1300 of this chapter.
3. Section 1305.03 is proposed to be revised to read as follows:

Sec. 1305.03 Distributions requiring order forms.

An order form (DEA Form 222) is required for each distribution of a
Schedule I or II controlled substance except to persons exempted from
registration under part 1301 of this chapter; which are exported from
the United States in conformity with the Act; or for delivery to a
registered analytical laboratory, or its agent approved by DEA.
4. Section 1305.06 is proposed to be amended to read as follows:

Sec. 1305.06 Procedure for executing order forms.

(a) Order forms shall be prepared and executed by the purchaser
simultaneously in triplicate by means of interleaved carbon sheets
which are part of the DEA Form 222. Order forms shall be prepared by
use of a typewriter, pen, or indelible pencil.
(b) Only one item shall be entered on each numbered line. An item
shall consist of one or more commercial or bulk containers of the same
finished or bulk form and quantity of the same substance. The last line
completed shall be noted on that form at the bottom of the form, in the
space provided. Order forms for carfentanil, etorphine hydrochloride,
and diprenorphine shall contain only these substances.
(c) The name and address of the supplier from whom the controlled
substances are being ordered shall be entered on the form. Only one
supplier may be listed on any form.
(d) Each order form shall be signed and dated by a person
authorized to sign an application for registration. The name of the
purchaser, if different from the individual signing the order form,
shall also be inserted in the signature space. Unexecuted order forms
may be kept and may be executed at a location other than the registered
location printed on the form, provided that all unexecuted forms are
delivered promptly to the registered location upon an inspection of
such location by any officer authorized to make inspections, or to
enforce, any Federal, State, or local law regarding controlled
substances.
5. Section 1305.07 is proposed to be amended to read as follows:

Sec. 1305.07 Power of attorney.

Any purchaser may authorize one or more individuals, whether or not
located at the registered location of the purchaser, to obtain and
execute order forms on his/her behalf by executing a power of attorney
for each such individual. The power of attorney shall be signed by the
same person who signed the most recent application for registration or
reregistration and by the individual being authorized to obtain and
execute order forms. The power of attorney shall be filed with the
executed order forms of the purchaser, and shall be retained for the
same period as any order form bearing the signature of the attorney.
The power of attorney shall be available for inspection together with
other order form records. Any power of attorney may be revoked at any
time by executing a notice of revocation, signed by the person who
signed (or was authorized to sign) the power of attorney or by a
successor, whoever signed the most recent application for registration
or reregistration, and filing it with the power of attorney being
revoked. The form for the power of attorney and notice of revocation
shall be similar to the following:

Power of Attorney for DEA Order Forms

----------------------------------------------------------------------
(Name of registrant)

----------------------------------------------------------------------
(Address of registrant)

(DEA registration number)---------------------------------------------

I, ________________ (name of person granting power), the
undersigned, who is authorized to sign the current application for
registration of the above-named registrant under the Controlled
Substances Act or Controlled Substances Import and Export Act, have
made, constituted, and appointed, and by these presents, do make,
constitute, and appoint
(name of attorney-in-fact),-------------------------------------------
my true and lawful attorney for me in my name, place, and stead, to
execute applications for books of official order forms and to sign
such order forms in requisition for Schedule I and II controlled
substances, in accordance with section 308 of the Controlled
Substances Act (21 U.S.C. 828) and part 1305 of Title 21 of the Code
of Federal Regulations. I hereby ratify and confirm all that said
attorney shall lawfully do or cause to be done by virtue hereof.
----------------------------------------------------------------------
(Signature of person granting power)

I, ________________ (name of attorney-in-fact), hereby affirm
that I am the person named herein as attorney-in-fact and that the
signature affixed hereto is my signature.

----------------------------------------------------------------------
(Signature of attorney-in-fact)

Witnesses:
1. ____________________.
2. ____________________.

Signed and dated on the ________ day of __________, (year), at
________________.

Notice of Revocation

The foregoing power of attorney is hereby revoked by the
undersigned, who is authorized to sign the current application for
registration of the above-named registrant under the Controlled
Substances Act of the Controlled Substances Import and Export Act.
Written notice of this revocation has been given to the attorney-in-
fact ________________ this same day.

----------------------------------------------------------------------
(Signature of person revoking power)
Witnesses:
1. ____________________.
2. ____________________.

Signed and dated on the ________ day of ____________, (year) ,
at ____________________.

[[Page 8529]]

6. Section 1305.12 is proposed to be amended by revising paragraph
(b) to read as follows:

Sec. 1305.12 Lost or stolen order forms.

* * * * *
(b) Whenever any used or unused order forms are stolen or lost
(otherwise than in the course of transmission) by any purchaser or
supplier, he/she shall immediately upon discovery of such theft or
loss, report the same to the Special Agent in Charge of the Drug
Enforcement Administration in the Divisional Office responsible for the
area in which the registrant is located, stating the serial number of
each form stolen or lost. If the theft or loss includes any original
order forms received from purchasers and the supplier is unable to
state the serial numbers of such order forms, he/she shall report the
date or approximate date of receipt thereof and the names and addresses
of the purchasers. If an entire book of order forms is lost or stolen,
and the purchaser is unable to state the serial numbers of the order
forms contained therein, he/she shall report, in lieu of the numbers of
the forms contained in such book, the date or approximate date of
issuance thereof. If any unused order form reported stolen or lost is
subsequently recovered or found, the Special Agent in Charge of the
Drug Enforcement Administration in the Divisional Office responsible
for the area in which the registrant is located shall immediately be
notified.
7. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

------------------------------------------------------------------------
Section Remove Add
------------------------------------------------------------------------
1305.04(b)...................... his............... his/her.
1305.05(b)...................... him (twice)....... him/her.
1305.08(a)...................... he................ he/she.
1305.08(a)...................... his (twice)....... his/her.
1305.09(b)...................... he................ he/she.
1305.09(d)...................... his ovn........... his/her own.
1305.10(a)...................... hall.............. shall.
1305.10(a)...................... he................ he/she.
1305.13(a)...................... He................ He/She.
1305.13(b)...................... he................ he/she.
1305.13(c)...................... he................ he/she.
1305.13(c)...................... 1305.06(e)........ 1305.06(d).
1305.14......................... he (twice)........ he/she.
1305.14......................... 1301.45 or 1301.46 1301.36.
1305.16(b)...................... he................ he/she.
------------------------------------------------------------------------

PART 1306--[AMENDED]

1. The authority citation for Part 1306 continues to read as
follows:

Authority: 21 U.S.C. 821, 829, 871(b).

2. Section 1306.02 is proposed to be revised to read as follows:

Sec. 1306.02 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.
3. Section 1306.11 is proposed to be amended by revising paragraphs
(a) and (d)(4), and adding a new paragraph (g) to read as follows:

Sec. 1306.11 Requirement of prescription.

(a) A pharmacist may dispense directly a controlled substance
listed in Schedule II, which is a prescription drug as determined under
the Federal Food, Drug, and Cosmetic Act, only pursuant to a written
prescription signed by the practitioner, except as provided in
paragraph (d) of this section. A prescription for a Schedule II
controlled substance may be transmitted by the practitioner or the
practitioner's agent to a pharmacy via facsimile equipment, provided
the original written, signed prescription is presented to the
pharmacist for review prior to the actual dispensing of the controlled
substance, except as noted in paragraph (e), (f), or (g) of this
section. The original prescription shall be maintained in accordance
with Sec. 1304.04(h) of this chapter.
* * * * *
(d) * * *
(4) Within 7 days after authorizing an emergency oral prescription,
the prescribing individual practitioner shall cause a written
prescription for the emergency quantity prescribed to be delivered to
the dispensing pharmacist. In addition to conforming to the
requirements of Sec. 1306.05, the prescription shall have written on
its face ``Authorization for Emergency Dispensing,'' and the date of
the oral order. The written prescription may be delivered to the
pharmacist in person or by mail, but if delivered by mail it must be
postmarked within the 7 day period. Upon receipt, the dispensing
pharmacist shall attach this prescription to the oral emergency
prescription which had earlier been reduced to writing. The pharmacist
shall notify the nearest office of the Administration if the
prescribing individual practitioner fails to deliver a written
prescription to him; failure of the pharmacist to do so shall void the
authority conferred by this paragraph to dispense without a written
prescription of a prescribing individual practitioner.
* * * * *
(g) A prescription prepared in accordance with Sec. 1306.05 written
for a Schedule II narcotic substance for a patient released by a
registered institution to a home hospice setting which continues to
provide daily skilled nursing care to the home hospice setting may be
transmitted by the practitioner or the practitioner's agent to the
dispensing pharmacy by facsimile. The practitioner or the
practitioner's agent will note on the prescription that the patient is
a hospice patient. The facsimile serves as the original written
prescription for purposes of this paragraph (g) and it shall be
maintained in accordance with Sec. 1304.04(h) of this chapter.
4. Section 1306.13 is proposed to be amended by revising paragraph
(b) to read as follows:

Sec. 1306.13 Partial filling of prescriptions.

* * * * *
(b) A prescription for a Schedule II controlled substance written
for a patient in a Long Term Care Facility (LTCF) or for a patient with
a medical diagnosis documenting a terminal illness may be filled in
partial quantities to include individual dosage units. If there is any
question whether a patient may be classified as having a terminal
illness, the pharmacist must contact the practitioner prior to
partially filling the prescription. The pharmacist must record on the
prescription whether the patient is ``terminally ill'' or an ``LTCF
patient.'' Both the pharmacist and the prescribing practitioner have a
corresponding responsibility to assure that the controlled substance is
for a terminally ill patient. The pharmacist must record on the
prescription whether the patient is ``terminally ill'' or an ``LTCF
patient.'' A prescription that is partially filled and does not contain
the notation ``terminally ill'' or ``LTCF patient'' shall be deemed to
have been filled in violation of the Act. For each partial filling, the
dispensing pharmacist shall record on the back of the prescription (or
on another appropriate record, uniformly maintained, and readily
retrievable) the date of the partial filling, quantity dispensed,
remaining quantity authorized to be dispensed, and the identification
of the dispensing pharmacist. The total quantity of Schedule II
controlled substances dispensed in all partial fillings must not exceed
the total quantity prescribed. Schedule II prescriptions for patients
in a LTCF or patients with a medical diagnosis documenting a terminal
illness shall be valid for a period not to exceed 60 days from the
issue date unless sooner terminated by the discontinuance of
medication.
* * * * *

[[Page 8530]]

5. Section 1306.14 is proposed to be amended by revising the
heading and adding a new paragraph (c) to read as follows:

Sec. 1306.14 Labeling of substances and filing of prescriptions.

* * * * *
(c) All written prescriptions and written records of emergency oral
prescriptions shall be kept in accordance with requirements of
Sec. 1304.04(h) of this chapter.
6. Section 1306.15 is proposed to be removed.
7. The center undesignated heading preceding Sec. 1306.21 and
Sec. 1306.21 are proposed to be revised to read as follows:

Controlled Substances Listed in Schedules III, IV, and V

Sec. 1306.21 Requirement of prescription.

(a) A pharmacist may dispense directly a controlled substance
listed in Schedule III, IV, or V which is a prescription drug as
determined under the Federal Food, Drug, and Cosmetic Act, only
pursuant to either a written prescription signed by a practitioner or a
facsimile of a written, signed prescription transmitted by the
practitioner or the practitioner's agent to the pharmacy or pursuant to
an oral prescription made by an individual practitioner and promptly
reduced to writing by the pharmacist containing all information
required in Sec. 1306.05, except for the signature of the practitioner.
(b) An individual practitioner may administer or dispense directly
a controlled substance listed in Schedule III, IV, or V in the course
of his/her professional practice without a prescription, subject to
Sec. 1306.07.
(c) An institutional practitioner may administer or dispense
directly (but not prescribe) a controlled substance listed in Schedule
III, IV, or V only pursuant to a written prescription signed by an
individual practitioner, or pursuant to a facsimile of a written
prescription or order for medication transmitted by the practitioner or
the practitioner's agent to the institutional practitioner-pharmacist,
or pursuant to an oral prescription made by an individual practitioner
and promptly reduced to writing by the pharmacist (containing all
information required in Sec. 1306.05 except for the signature of the
individual practitioner), or pursuant to an order for medication made
by an individual practitioner which is dispensed for immediate
administration to the ultimate user, subject to Sec. 1306.07.
8. Section 1306.23 is proposed to be amended by revising the
introductory text to read as follows:

Sec. 1306.23 Partial filling of prescriptions.

The partial filling of a prescription for a controlled substance
listed in Schedule III, IV, or V is permissible, provided that:
* * * * *
9. Section 1306.24 is proposed to be revised to read as follows:

Sec. 1306.24 Labeling of substances and filing of prescriptions.

(a) The pharmacist filling a prescription for a controlled
substance listed in Schedule III, IV, or V shall affix to the package a
label showing the pharmacy name and address, the serial number and date
of initial filling, the name of the patient, the name of the
practitioner issuing the prescription, and directions for use and
cautionary statements, if any, contained in such prescription as
required by law.
(b) The requirements of paragraph (a) of this section do not apply
when a controlled substance listed in Schedule III, IV, or V is
prescribed for administration to an ultimate user who is
institutionalized: provided, that:
(1) Not more than a 34-day supply or 100 dosage units, whichever is
less, of the controlled substance listed in Schedule III, IV or V is
dispensed at one time;
(2) The controlled substance listed in Schedule III, IV or V is not
in the possession of the ultimate user prior to administration;
(3) The institution maintains appropriate safeguards and records
the proper administration, control, dispensing, and storage of the
controlled substance listed in Schedule III, IV or V; and
(4) The system employed by the pharmacist in filling a prescription
is adequate to identify the supplier, the product and the patient, and
to set forth the directions for use and cautionary statements, if any,
contained in the prescription or required by law.
(c) All prescriptions for controlled substances listed in Schedules
III, IV and V shall be kept in accordance with Sec. 1304.04(h) of this
chapter.

Sec. 1306.25 [Removed]

10. Section 1306.25 is proposed to be removed.

Sec. 1306.26 [Redesignated as Sec. 1306.25 and amended]

11. Section 1306.26 is proposed to be redesignated as Sec. 1306.25
and amended by revising paragraphs (a) and (b) to read as follows:

Sec. 1306.25 Transfer between pharmacies of prescription information
for Schedules III, IV, and V controlled substances for refill purposes.

(a) The transfer of original prescription information for a
controlled substance listed in Schedules III, IV or V for the purpose
of refill dispensing is permissible between pharmacies on a one time
basis only. However, pharmacies electronically sharing a real-time, on-
line database may transfer up to the maximum refills permitted by law
and the prescriber's authorization. Transfers are subject to the
following requirements:
(1) The transfer is communicated directly between two licensed
pharmacists and the transferring pharmacist records the following
information:
(i) Write the word ``VOID'' on the face of the invalidated
prescription.
(ii) Record on the reverse of the invalidated prescription the
name, address and DEA registration number of the pharmacy to which it
was transferred and the name of the pharmacist receiving the
prescription information.
(iii) Record the date of the transfer and the name of the
pharmacist transferring the information.
(b) The pharmacist receiving the transferred prescription
information shall reduce to writing the following:
(1) Write the word ``transfer'' on the face of the transferred
prescription.
(2) Provide all information required to be on a prescription
pursuant to 21 CFR 1306.05 and include:
(i) Date of issuance of original prescription;
(ii) Original number of refills authorized on original
prescription;
(iii) Date of original dispensing;
(iv) Number of valid refills remaining and date(s) and locations of
previous refill(s);
(v) Pharmacy's name, address, DEA registration number and
prescription number from which the prescription information was
transferred;
(vi) Name of pharmacist who transferred the prescription.
(vii) Pharmacy's name, address, DEA registration number and
prescription number from which the prescription was originally filled;
(3) The original and transferred prescription(s) must be maintained
for a period of two years from the date of last refill.
* * * * *

Sec. Undesignated center heading and Sec. 1306.31 [Removed]

12. The undesignated heading preceding Sec. 1306.31 and
Sec. 1306.31 are proposed to be removed.

[[Page 8531]]

Sec. 1306.32 [Redesignated as Sec. 1306.26 and amended]

13. Section 1306.32 is proposed to be redesignated as Sec. 1306.26
and the introductory text and paragraph (a) are revised to read as
follows:

Sec. 1306.26 Dispensing without prescription.

A controlled substance listed in Schedules II, III, IV or V which
is not a prescription drug as determined under the Federal Food, Drug,
and Cosmetic Act, may be dispensed by a pharmacist without a
prescription to a purchaser at retail, provided that:
(a) Such dispensing is made only by a pharmacist (as defined in
Part 1300 of this chapter), and not by a nonpharmacist employee even if
under the supervision of a pharmacist (although after the pharmacist
has fulfilled his professional and legal responsibilities set forth in
this section, the actual cash, credit transaction, or delivery, may be
completed by a nonpharmacist);
* * * * *
14. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

------------------------------------------------------------------------
Section Remove Add
------------------------------------------------------------------------
1306.03(a)(2)................... 1301.24(c)........ 1301.22(c).
1306.03(a)(2)................... 1301.25........... 1301.23.
1306.05(b)...................... 1301.24(c)........ 1301.22(c).
1306.05(c)...................... 1301.25........... 1301.22(c).
1306.22(a)(2)................... practioner........ practitioner.
1306.22(b)...................... retrival.......... retrieval.
1306.22(b)(2)................... duing............. during.
1306.22(b)(4)................... Compliance........ Diversion.
------------------------------------------------------------------------

PART 1307--[AMENDED]

1. The authority citation for part 1307 continues to read as
follows:

Authority: 21 U.S.C. 821, 822(d), 871(b).

2. Section 1307.01 is proposed to be revised to read as follows:

Sec. 1307.01 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or Part 1300 of this chapter.
3. Section 1307.02 is proposed to be revised to read as follows:

Sec. 1307.02 Application of State law and other Federal law.

Nothing in this chapter shall be construed as authorizing or
permitting any person to do any act which such person is not authorized
or permitted to do under other Federal laws or obligations under
international treaties, conventions or protocols, or under the law of
the State in which he/she desires to do such act nor shall compliance
with such parts be construed as compliance with other Federal or State
laws unless expressly provided in such other laws.
4. Section 1307.03 is proposed to be revised to read as follows:

Sec. 1307.03 Exceptions to regulations.

Any person may apply for an exception to the application of any
provision of this chapter by filing a written request stating the
reasons for such exception. Requests shall be filed with the
Administrator, Drug Enforcement Administration, Department of Justice,
Washington, DC 20537. The Administrator may grant an exception in his
discretion, but in no case shall he/she be required to grant an
exception to any person which is otherwise required by law or the
regulations cited in this section.

Sec. 1307.12 [Removed]

5. Section 1307.12 is proposed to be removed.

Sec. 1307.13 [Redesignated as Sec. 1307.12]

6. Section 1307.13 is proposed to be redesignated as Sec. 1307.12.

Sec. 1307.14 [Removed]

7. Section 1307.14 is proposed to be removed.

Sec. 1307.15 [Redesignated as Sec. 1307.13]

8. Section 1307.15 is proposed to be redesignated as Sec. 1307.13.
9. Section 1307.21 is proposed to be amended by revising paragraph
(a) to read as follows:

Sec. 1307.21 Procedure for disposing of controlled substances.

(a) Any person in possession of any controlled substance and
desiring or required to dispose of such substance may request the
Special Agent in Charge of the Administration in the area in which the
person is located for authority and instructions to dispose of such
substance. The request should be made as follows:
(1) If the person is a registrant, he/she shall list the controlled
substance or substances which he/she desires to dispose of on DEA Form
41, and submit three copies of that form to the Special Agent in Charge
in his/her area; or
(2) If the person is not a registrant, he/she shall submit to the
Special Agent in Charge a letter stating:
(i) The name and address of the person;
(ii) The name and quantity of each controlled substance to be
disposed of;
(iii) How the applicant obtained the substance, if known; and
(iv) The name, address, and registration number, if known, of the
person who possessed the controlled substances prior to the applicant,
if known.
* * * * *
10. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

------------------------------------------------------------------------
Section Remove Add
------------------------------------------------------------------------
1307.11(a)(2)................... 1304.24(e)........ 1304.22(c).
1307.11(a)(2)................... 1304.24(c)........ 1304.22(c).
1307.11(a)(4)................... 1301.28........... 1301.25.
1307.11(b)...................... 1301.28........... 1301.25.
1307.22......................... 28083............. 20537.
------------------------------------------------------------------------

PART 1308--[AMENDED]

1. The authority citation for part 1308 continues to read as
follows:

Authority: 21 U.S.C. 811, 812, 871(b).

2. Section 1308.02 is proposed to be revised to read as follows:

Sec. 1308.02 Definitions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.

Sec. 1308.04 [Removed]

3. Section 1308.04 is proposed to be removed.
4. Section 1308.24 is proposed to be amended by removing the Exempt
Chemical Preparations Table and revising paragraphs (a) and (i) to read
as follows:

Sec. 1308.24 Exempt chemical preparations.

(a) The chemical preparations and mixtures approved pursuant to
Sec. 1308.23 are exempt from application of sections 302, 303, 305,
306, 307, 308, 309, 1002, 1003 and 1004 of the Act (21 U.S.C. 822-823,
825-829, 952-954) and Sec. 1301.74 of this chapter, to the extent
described in paragraphs (b) to (h) of this section. Substances set
forth in paragraph (j) shall be exempt from the application of Sections
305, 306, 307, 308, 309, 1002, 1003 and 1004 of the Act (21 U.S.C. 825-
829, 952-954) and Secs. 1301.71-1301.73 and 1301.74 (a), (b), (d), (e)
and (f) of this chapter to the extent as hereinafter may be provided.
* * * * *
(i) A listing of exempt chemical preparations may be obtained by
submitting a written request to the Drug and Chemical Evaluation
Section, Drug

[[Page 8532]]
Enforcement Administration, Washington, DC 20537.
* * * * *
5. In Section 1308.26(a) the Table of Excluded Veterinary Anabolic
Steroid Implant Products is proposed to be removed. As revised,
Sec. 1308.26(a) is proposed to read as follows:

Sec. 1308.26 Excluded veterinary anabolic steroid implant products.

(a) The anabolic steroid-containing products, which are expressly
intended for administration through implants to cattle or other
nonhuman species and which have been approved by the Secretary of
Health and Human Services for such administration are excluded from all
schedules pursuant to Section 102(41)(B)(I) of the Act (21 U.S.C.
802(41)(B)(I)). A listing of the excluded products may be obtained by
submitting a written request to the Drug and Chemical Evaluation
Section, Drug Enforcement Administration, Washington DC 20537.
* * * * *
6. In Sec. 1308.32, the Table of Exempted Prescription Products is
proposed to be removed. As revised Sec. 1308.32 is proposed to read as
follows:

Sec. 1308.32 Exempted prescription products.

The compounds, mixtures, or preparations which contain a
nonnarcotic controlled substance listed in Sec. 1308.12(e) or in
Sec. 1308.13 (b) or (c) or in Sec. 1308.14 or in Sec. 1308.15 listed in
the Table of Exempted Prescription Products have been exempted by the
Administrator from the application of sections 302 through 305, 307
through 309, 1002 through 1004 of the Act (21 U.S.C. 822-825, 827-829,
and 952-954) and Sections 1301.13, 1301.22, and Secs. 1301.71 through
1301.76 of this chapter for administrative purposes only. An exception
to the above is that those products containing butalbital shall not be
exempt from the requirement of 21 U.S.C. 952-954 concerning
importation, exportation, transshipment and in-transit shipment of
controlled substances. Any deviation from the quantitative composition
of any of the listed drugs shall require a petition of exemption in
order for the product to be exempted. A listing of the Exempted
Prescription Products may be obtained by submitting a written request
to the Drug and Chemical Evaluation Section, Drug Enforcement
Administration, Washington, DC 20537.
7. In Section 1308.34, the Table of Exempt Anabolic Steroid
Products is proposed to be removed. As revised, Sec. 1308.34 is
proposed to read as follows:

Sec. 1308.34 Exempt anabolic steroid products.

The anabolic steroid containing compounds, mixtures, or
preparations which have been exempted by the Administrator from
application of sections 302 through 309 and 1002 through 1004 of the
Act (21 U.S.C. 822-829 and 952-954) and Secs. 1301.13, 1301.22, and
1301.71 through 1301.76 of this chapter for administrative purposes
only may be obtained by submitting a written request to the Drug and
Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537.
8. Section 1308.42 is proposed to be revised to read as follows:

Sec. 1308.42 Purpose of hearing.

If requested by any interested person after proceedings are
initiated pursuant to Sec. 1308.43 of this chapter, the Administrator
shall hold a hearing for the purpose of receiving factual evidence and
expert opinion regarding the issues involved in the issuance, amendment
or repeal of a rule issuable pursuant to Section 201(a) of the Act (21
U.S.C. 811(a)). Extensive argument should not be offered into evidence
but rather presented in opening or closing statements of counsel or in
memoranda or proposed findings of fact and conclusions of law.
Additional information relating to hearings to include waivers or
modification of rules, request for hearing, burden of proof, time and
place, and final order are set forth in Part 1316 of this chapter.

Sec. 1308.43 [Removed]

9. Section 1308.43 is proposed to be removed.

Sec. 1308.44 [Redesignated as Sec. 1308.43]

10. Sections 1308.44 is proposed to be redesignated as Sec. 1308.43
and the citation ``1308.45'' in paragraph (f) is changed to read
``1308.44''.

Sec. 1308.45 [Redesignated as Sec. 1308.44]

11. Section 1308.45 is proposed to be redesignated as 1308.44 and
the citation ``1308.48'' in paragraph (e) changed to read ``1308.45''.

Sec. 1308.46 and 1308.47

[Removed]

12. Sections 1308.46 and 1308.47 are proposed to be removed.

Secs. 1308.48--1308.50 [Redesignate as Secs. 1308.45-1308.47]

13. Sections 1308.48 through 1308.50 are proposed to be
redesignated as Secs. 1308.45 through 1308.47.

Sec. 1308.5 [Removed]

14. Section 1308.51 is proposed to be removed.

Sec. 1308.52 [Redesignated as Sec. 1308.49 and corrected]

15. Section 1308.52 is proposed to be redesignated as Sec. 1308.49
and the typographical error ``withott'' in the introductory text is
corrected to read ``without''.
16. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

------------------------------------------------------------------------
Section Remove Add
------------------------------------------------------------------------
Table of Contents for Part 1308. 1308.52 sheduling. 1308.52
scheduling.
1308.03(a)...................... 1301.44 and 1301.35.
1311.43.
1308.12(g)...................... prectrsors........ precursors.
1308.13(b)(1)................... quantitive........ quantitative.
1308.13(b)(1)................... lirted............ listed.
1308.13(b)(1)................... 308.32............ 1308.32.
1308.22......................... nonarcotic........ nonnarcotic.
1308.23(c)(7)................... 1302.01........... Part 1300 of this
chapter.
1308.23(f)...................... revoje............ revoke.
1308.24(d)...................... Drug Control...... Drug and Chemical
Evaluation.
1308.33(a)...................... 1308.02........... Part 1300 of this
chapter.
1308.33(b)...................... 1308.02........... Part 1300 of this
chapter.
------------------------------------------------------------------------

PART 1309--[AMENDED]

1. The authority citation for part 1309 continues to read as
follows:

Authority: 21 U.S.C. 821, 822, 823, 824, 830, 871(b), 875, 877,
958.

2. Section 1309.02 is proposed to be revised to read as follows:

Sec. 1309.02 Definitions.

Any term used in this part shall have the definition set forth in
Section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.

Secs. 1309.53 and 1309.57 [Removed] and Secs. 1309.54-
1309.56 [Redesignated as Secs. 1309.53-1309.55]

3. Sections 1309.53 and 1309.57 are proposed to be removed and
Secs. 1309.54 through 1309.56 are proposed to be redesignated as
Secs. 1309.53 through 1309.55.
4. In addition to the proposed amendments set forth above, DEA is
proposing to remove the words ``Section

[[Page 8533]]
1310.01(f)(1)(iv) and add in their place the words ``Section
1300.01(b)(28)(i)(D)'' in the following places:
(a) Section 1309.02(g)
(b) Section 1309.21 (a) and (b)
(c) Section 1309.25 (a) and (b); and
(d) Section 1309.71(a)(2).

PART 1310--[AMENDED]

1. The authority citation for part 1310 continues to read as
follows:

Authority: 21 U.S.C. 802, 830, 871(b).

2. Section 1310.01 is proposed to be revised to read as follows:

Sec. 1310.01 Definitions.

Any term used in this part shall have the definition set forth in
section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.

Sec. 1310.05 [Amended]

2. Section 1310.05(c) is proposed to be amended removing the words
``as defined in Sec. 1310.01(i)'' and ``as defined in Sec. 1310.01(j)''

Sec. 1310.08 [Amended]

3. Section 1310.08, introductory text, is proposed to be amended
removing the words ``containted in 21 CFR 1310.01(f) and 1313.02(d)''

Sec. 1310.09 [Removed]

4. Section 1310.09 is proposed to be removed.
5. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

--------------------------------------------------------------------------------------------------------------------------------------------------------
Section Remove Add
--------------------------------------------------------------------------------------------------------------------------------------------------------
1310.10(a).................................... 1310.01(f)(1)(iv) 1300.01(b)(28)(i)(D).
1310.14(a).................................... 1310.01(f)(1)(iv)(A) 1300.01(b)(28)(i)(D)(1).
1310.15(d).................................... 1310.01(f)(1)(iv)(A) 1300.01(b)(28)(i)(D)(1).
--------------------------------------------------------------------------------------------------------------------------------------------------------

PART 1311--[REMOVED AND RESERVED]

Part 1311 is proposed to be removed and reserved.

PART 1312--[AMENDED]

1. The authority citation for part 1312 continues to read as
follows:

Authority: 21 U.S.C. 952, 953, 954, 957, 958.

2. Section 1312.02 is proposed to be revised to read as follows:

Sec. 1312.02 Defintions.

Any term contained in this part shall have the definition set forth
in section 102 of the Act (21 U.S.C. 802) or Part 1300 of this chapter.
3. Part 1312 is proposed to be amended to remove the words, ``1405
EYE Street, NW.'', in the following sections:
(a) 1312.12(a);
(b) 1312.16(b);
(c) 1312.18(b);
(d) 1312.19(b);
(e) 1312.22(a);
(f) 1312.24(a);
(g) 1312.27(a);
(h) 1312.27(b)(5)(iv);
(i) 1312.28(d);
(j) 1312.31(b); and
(k) 1312.32(a).
4. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

------------------------------------------------------------------------
Section Remove Add
------------------------------------------------------------------------
1312.12(a).................. Drug Control Section Drug Operations
Section.
1312.14(a).................. Drug Control Section Drug Operations
Section.
1312.16(b).................. Drug Control Section Drug Operations
Section.
1312.17..................... 304................. 1304.
1312.18(b).................. Drug Control Section Drug Operations
Section.
1312.18(c).................. (or BND)............ ....................
1312.19(a).................. Drug Control Section Drug Operations
Section.
1312.19(b).................. Drug Control Section Drug Operations
Section.
1312.22(a).................. Drug Control Section Drug Operations
Section.
1312.24(a).................. Bureau.............. Administration.
1312.24(a).................. Drug Control Section Drug Operations
Section.
1312.25..................... Drug Control Section Drug Operations
Section.
1312.27(a).................. regirtered.......... registered.
1312.27(a).................. Drug Control Section Drug Operations
Section.
1312.27(b)(5)(iii).......... inital.............. initial.
1312.27(b)(5)(iv)........... Drug Control Section Drug Operations
Section.
1312.28(d).................. Drug Control Section Drug Operations
Section.
1312.28(d).................. 1327.27(b)(4)....... 1312.27(b0(4).
1312.31(b).................. Drug Control Section Drug Operations
Section.
1312.32(a).................. Drug Control Section Drug Operations
Section.
------------------------------------------------------------------------

PART 1313--[AMENDED]

1. The authority citation for part 1313 continues to read as
follows:

Authority: 21 U.S.C. 802, 830, 871(b), 971.

2. Section 1313.02 is proposed to be revised to read as follows:

Sec. 1313.02 Definitions.

Any term used in this part shall have the definition set forth in
section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.
3. Section 1313.15(a) is proposed to be amended by removing the
words ``Sec. 1313.02(i)'' and replace them with the words
``Sec. 1300.01(b)(13)''
4. Section 1313.21(c)(1) is proposed to be amended by removing the
words ``as defined Sec. 1313.02(j)''
5. Section 1313.24(a) is proposed to be amended by removing the
words ``Sec. 1313.02(j)'' and replacing them with the words
``Sec. 1300.01(b)(12)''

[[Page 8534]]

PART 1316--[AMENDED]

1. The authority citation for part 1316 continues to read as
follows:

Authority: 21 U.S.C. 822(f), 871(b), 880, 958(f), 965.

2. Section 1316.02 is proposed to be amended by revising paragraph
(g) to read as follows:

Sec. 1316.02 Definitions.

* * * * *
(g) Any term not defined in this part shall have the definition set
forth in section 102 of the Act (21 U.S.C. 802) or part 1300 of this
chapter.
3. Section 1316.13 is proposed to be amended by revising the text
to read as follows:

Sec. 1316.13 Frequency of administrative inspections.

Except where circumstances otherwise dictate, it is the intent of
the Administration to inspect all manufacturers of controlled
substances listed in Schedules I and II and distributors of controlled
substances listed in Schedule I once each year. Distributors of
controlled substances listed in schedules II through V and
manufacturers of controlled substances listed in Schedules III through
V shall be inspected as circumstances may require, based in part on the
registrant's history of compliance with the requirements of this
chapter and maintenance of effective controls and procedures to guard
against the diversion of controlled substances.
4. Section 1316.42 is proposed to be amended by revising paragraph
(h) to read as follows:

Sec. 1316.42 Definitions.

* * * * *
(h) Any term not defined in this part shall have the definition set
forth in section 102 of the Act (21 U.S.C. 802) or part 1300 of this
chapter.
5. Section 1316.71 is proposed to be amended by revising paragraph
(f) to read as follows:

Sec. 1316.71 Definitions.

* * * * *
(f) Any term not defined in this part shall have the definition set
forth in section 102 of the Act (21 U.S.C. 802) or part 1300 of this
chapter.
6. In addition to the proposed amendments set forth above, DEA is
proposing to amend each section indicated in the left column by
removing the words indicated in the middle column and adding the words
in the right column:

----------------------------------------------------------------------------------------------------------------
Section Remove Add
----------------------------------------------------------------------------------------------------------------
1316.03, introductory text Adminirtrator Administrator.
1316.05 1314.06 1316.06.
1316.05 1316.09-1316.14 1316.09-1316.13.
1316.23(b) 1405 I Street ....................................
1316.24(c) 1316.21(b) 1316.23(b).
1316.24(c) 1316.22(b) 1316.24(b).
1316.41 1303.41-1303.47 1303.31-1303.37.

1313.51-1313.57.
1316.46(b)(1) 1301.32(a)(3) 1301.32(a)(6).
1316.52(a) 1301.60 1301.56.
1316.77(a) Forward Forward.
1316.81 proceeeding proceeding.
----------------------------------------------------------------------------------------------------------------

Dated: February 26, 1996.
Stephen H. Greene,
Deputy Administrator, Drug Enforcement Administration.
[FR Doc. 96-4663 Filed 3-4-96; 8:45 am]
BILLING CODE 4410-09-P

Visit the Official Version

Document Information

Published:: 03/05/1996
Department:: Drug Enforcement Administration
Entry Type:: Proposed Rule
Action:: Proposed rule.
Document Number:: 96-4663
Dates:: Written comments or objections must be received by July 3, 1996.
Pages:: 8503-8534 (32 pages)
Docket Numbers:: DEA Number 139P
PDF File:: 96-4663.pdf
CFR: (127): 21 CFR 1301.34); 21 CFR 1308.26(a); 21 CFR 1310.02(b); 21 CFR 1300.01(b)(12); 21 CFR 1308.11(d); More ...